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ABSTRACT
In Australia, prostate cancer is the second most frequently diagnosed cancer in men and
the third most common cause of cancer death. Breast cancer is the most common form of
cancer in Australian women. Radiotherapy plays a significant role in the treatment of
prostate and breast cancers. The aim of in-vivo skin dosimetry is to measure the absorbed
dose to the skin during radiotherapy. The skin is extremely sensitive to radiation. Any
overdose can result in significant skin problems (skin toxicity). The silicon detector is a
common type of detector utilised in medical dosimetry. Silicon epitaxial diode are being
used as alternative to conventional silicon detector due to its various advantageous
properties, such as relatively small sensitive volume and increased radiation hardness.
The new n-type skin diode was designed by the Centre for Medical Radiation Physics at
the University of Wollongong.
This work investigates the performance of the new n-type epitaxial skin diode detector
for in-vivo skin dosimetry in external beam radiotherapy and brachytherapy and aims to
develop an accurate and reliable in-vivo dosimetry system that could be used as a quality
assurance tool during radiotherapy.
The first part focusses on the characterisation of the skin diode for in-vivo skin dosimetry
for external beam radiotherapy, in which various parameters were investigated such
current-voltage (I-V) characteristics, capacitance-voltage (C-V) characteristics, linearity,
percentage depth dose (PDD), output factor (OF), energy dependence, angular
dependence and dose per pulse (DPP). The response of skin diode detector showed a
feasible result for linearity, PDD, OF, DPP, energy dependence and angular dependence.
In the second part of this thesis, the performance characteristics of the skin diode
dosimeter are studied when irradiated with an Ir-192 HDR brachytherapy source. The
ability of the skin diode to measure the dose at different distances from the source, and
i

from various angles of irradiation is investigated and the results compared with TG43
calculated values. Moreover, a skin diode detector flip sensitivity test was performed to
study the effect of changing skin diode detector orientation. In addition, a comparison of
backscatter with and without air cavity was carried out. Monte Carlo simulations using
the GEANT4 toolkit were run using to gain a better understanding of how these
dosimeters could react when used in brachytherapy. An Ir-192 source was created to
simulate the St. George Hospital flexisource HDR brachytherapy source and the skin
diode detector was modelled. The percentage depth dose (PDD) and angular dependence
were performed.
In the third part of this thesis, the skin diode detector in clinical experiments was assessed
to measure the skin dose under two treatment modalities: HDR brachytherapy and
VMAT. The first experiment was done using three skin diode detectors integrated with
the TRUS-probe, to measure the skin dose on the anterior wall of the rectum during
prostate treatment. The second experiment was done to examine the dosimetric accuracy
of the new skin diode dosimeters for measuring skin dose during high dose-rate breast
brachytherapy and compare it with TPS, EBT3 films, and MOSkin dosimeters. The third
experiment was done to identify the suitability of the skin diode detector for skin dose
measurements during breast therapy using VMAT plan. The new n-type epitaxial skin
diode detector proved to be a good and effective in-vivo real-time skin dosimetry tool to
prevent certain systematic set-up errors during the treatment of breast and prostate cancer
HDR BT and VMAT.
KEYWORDS: Skin diode dosimeter, high dose rate brachytherapy, external beam
radiotherapy, in-vivo dosimetry, quality assurance, Prostate HDR brachytherapy, Brest
radiotherapy, electrical characterisation, on-line measurements.
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CHAPTER 1: Introduction
1.1 Preface
Cancer is the world's second major cause of death and is responsible for estimated 9.6
million deaths globally in 2018 [1]. Approximately 1 in 6 deaths were attributed to cancer
globally [1]. In 2013, 24,972 deaths from cancer were recorded in Australia according to
the Australian Cancer Incidence and Morbidity workbook (ACIM) [2]. The probability
of dying due to cancer is 1 in 5 for Australians aged over 85. The “All Cancer for
Australia” report revealed that more than 100,000 new cancer cases were diagnosed in
2007 and this number is expected to become higher in the upcoming years [3]. 12 million
deaths from cancer in 2030 is the prediction of the World Health Organization (WHO)
[4]. The comprehensive aim of radiotherapy is to deliver a radiation dose to specified
cancerous target while sparing healthy tissues in the surrounding area. This means the
balance between the cure of the disease and the probability of radiation induced
complications is important. Therefore, the need for precision and accuracy in radiotherapy
is very critical because a small increase in radiation dose will lead to significant impacts
on the probability of healing as well as increasing the probability of inducing detrimental
impacts in the patient. Treatment options for cancer rely upon the disease extent and
includes surgery, chemotherapy, hormone therapy and radiotherapy which covers
external beam radiotherapy (EBRT) and brachytherapy and is further subdivided into low
dose rate and high dose rate (LDR & HDR) therapies. A combination of any two of these
treatments can also be used.
The treatment options to be discussed in this project are high dose rate brachytherapy
(HDR) and external beam radiotherapy (EBRT). In HDR brachytherapy, the radiation
source is implanted in or near to the specified target in the patient, while EBRT is
1

performed basically with photon beams of high-energy x-rays, commonly produced by
linear accelerators (LINACs).
The achievement of accurate and reproducible radiation doses to the patients during
cancer treatment gives the maximum benefit in radiotherapy. Therefore, different studies
have included dosimetric measurements and positioning methods to achieve optimal
accuracy in brachytherapy treatment [5]. A previous study by Seymour et al. [6], provided
a detection method for errors in HDR prostate brachytherapy using a PTW diode array
type 9112 for in-vivo dosimetry. Accurate monitoring of the dose delivered to patient is
one of the main challenging issues during the use of radiation treatment, not only at the
targeted volume but also along the whole dose path through the body’s healthy tissues.
The skin is a difficult region to monitor during dose delivery in treatment. Hence it is
important to find a suitable detector for skin dosimetry to get accurate and reliable
measurements for skin doses.
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1.2 Thesis aim and objectives
The aim of the thesis was to study and use the new skin diode dosimeter (N-type) for
different dosimetry applications in radiotherapy. The work summarized in this thesis
investigates the following objectives:
1. Determine the dosimetric characteristics of skin diode dosimeter when
irradiated with an Ir-192 HDR brachytherapy source. Establish the
capability for measuring the dose at different distances from the radioactive
source, and from different angles of irradiation, and under different scatter
conditions.
2. Determine experimental dose measurements with skin diodes in phantom,
where in skin diodes are attached to a replica ultrasound probe to examine
this method for in-vivo dosimetry and this will allow evaluation of rectal
dose obtained by a treatment planning system when measured dose during
HDR prostate treatment.
3. Determine experimental dose measurements with a skin diode dosimeter on
a breast phantom to determine real-time in-vivo skin dose in HDR-BT.
4. Investigate the skin diode dosimeter characteristics when irradiated with a
6 MV photon beam by a linear accelerator (Varian model 2100X LINAC)
in two different modes (flattened (FF) and unflattened (FFF) megavoltage
beams. Evaluate linearity, the response at different depths, dose per pulse
and response at different field sizes.
5. Investigate the energy response of the skin diode in a kilovoltage (kV) xray beam source.
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6. Evaluate the skin diode dosimeter for breast surface dose measurements
with a LINAC and compare it with a treatment planning system (TPS)
calculated values.
The overall aim of this thesis is to investigate the characteristics of the new skin diode
dosimeter developed by the UOW CMRP with a water equivalent depth (WED) of 70 μm
to be used in brachytherapy and external beam radiotherapy. The dosimeter is designed
to address the issue of skin dosimetry with its capability for real-time measurements and
it shows promise as a tool to measure the skin dose to the rectal wall or breast while
performing HDR brachytherapy dosimetry and external beam radiotherapy of these
regions.

MOSkin detectors were designed to measure the doses at interfaces, so

consequently they are ideal for in-vivo skin dosimetry. MOSkin dosimeters, however, are
disposable, hence they may be expensive for routine clinical use. In comparison, the skin
diode is aimed at offering a more permanent and cost-effective solution.

1.3 Structure of the thesis
This thesis consists of 10 chapters. Chapter 1 introduces the aims and the objectives of
the thesis. Following this introductory, Chapter 2 presents the relevant literature related
to the work introduced in this thesis. It provides background information about
radiotherapy, skin dosimetry, an overview of prostate and breast cancer, in-vivo
dosimetry and principles of silicon diode detectors, Monte Carlo simulation and the
GEANT4 toolkit. In addition, this chapter provide information about the available in-vivo
dosimeters.
Chapter 3 describes the components used in this thesis; detectors, readout systems and
phantoms. It starts by describing the skin diode and MOSkin detectors and then the data
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acquisition systems used and their interfaces. Moreover, there is a description about the
phantoms that were used for the treatment plan delivery.
Chapter 4 introduces the characterisation of the new skin diode performance by
measuring the current-voltage (I-V) and capacitance-voltage (C-V) characteristics.
The following chapter of this thesis, Chapter 5 introduces Monte Carlo simulation
performed to “benchmark” the skin diode characteristics. Two models were simulated: a
“liquid water” model and a “silicon detector” model.
Chapter 6 introduces the characterisation of the new skin diodes in a high energy photon
beam. The calibration of the dosimeters, linearity, Percentage Depth Doses, and Output
Factors were carried out. Comparisons with a Wellhöfer compact ionisation chamber
(CC13) were performed.
Chapter 7 introduces the energy dependence of the new skin diodes using a kilovoltage
photon beam. In addition, the dose per pulse dependence and angular dependence were
measured in this chapter.
Chapter 8 covers the characterisation of the new skin diodes in HDR brachytherapy. The
calibration, depth dose response, radial angular response, azimuthal angular response, flip
sensitivity variation and a comparison of backscatter condition were performed.
In Chapter 9 the potential of using skin diode as a quality assurance tool in HDR BT
treatment was assessed by comparing the dose measured with skin diodes to the dose
calculated by the treatment plan during treatment delivery with a remote radioactive
source “afterloader”.

5

At the end of this thesis, Chapter 10 concludes this study’s work involving epitaxial skin
diode dosimeters as a dosimetry tool for HDR BT and EBRT quality assurance. Some
recommendations for future work are provided to improve the performance of the skin
diode dosimeters.
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CHAPTER 2: Literature Review
The goal of this chapter is to provide a background understanding of radiotherapy,
brachytherapy for prostate and breast cancer treatment and the different treatment
modalities. Starting with brief introduction to prostate cancer, the increased incidence of
cancer and common cancer treatment modalities, followed by a brief introduction to
breast cancer and treatment options.

2.1 Overview of Prostate Cancer
The prostate is a small gland in the male reproductive system. It is located in the pelvic
region between the penis and the bladder, anteriorly to the rectum. It is walnut sized and
shaped. For adult males, it is approximately 4 cm in length and 20 g in weight. The urethra
passes via the centre of the prostate to the penis. The distance between the prostate and
the rectum is 5.8 ± 0.7 mm for normal male adults of near-average body mass [7]. The
anatomy of the prostate illustrates in Figure 2.1. The prostate primary function is to
produce and store seminal fluid. Since many critical organs surround the prostate, it is
important to have a high accuracy of radiation delivery to treat prostate cancer.
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Figure 2.1: Sagittal cross-section illustrating the male reproductive system [8].

Prostate cancer is a major type of cancer that is diagnosed in Australia [9]. The abnormal
growth of prostate cells leads to a malignant tumour. The origin of the prostate
adenocarcinoma is the epithelial cells of the prostate [5]. The expansion of prostate cancer
cells to other parts of the body (metastasis), such as lymph nodes, bones and bladder, can
be reduced by the early detection of primary cancer in the prostate.
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Prostate cancer is the main cause of cancer-death in Australian men and is mostly
common in elderly men. In Australia, 98% of men diagnosed with prostate cancer are 50
years old or over [10]. In 2012, there were 3,079 deaths cases from prostate cancer in
Australia, according to the Australian Institute of Health and Welfare (AIHW). In
addition, the rate of age-standardised mortality was 28 deaths per 100,000 males and
prostate cancer is the second leading cause of mortality among men in Australia. In 2015,
it was predicted that the mortality rate would rise up to 3,440 cases per year in total,
although the age-standardised mortality rate per population would be the same as in 2012
and prostate cancer would remain as the second major cause of death among males [3].
The rate of prostate cancer in Australia has increased over the last two decades. However,
the death rate has been reduced due to the early detection and successful treatment
methods. Development of prostate cancer is ambiguous despite research suggesting that
its occurrence is related to genetic and dietary factors [11].
There are many factors that increase the risk of prostate cancer, which include age, family
history of disease, ethnicity, hormones, diet, radiation exposure and other socioeconomic
consideration factor [4]. For men over the age of 65, age plays a major role in prostate
cancer. The age-specific incidence rates for 2012 and age-specific mortality rates for 2013
of prostate cancer are plotted in Figures 2.2 & 2.3 respectively [12].
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Figure 2.2: Age-specific incidence of prostate cancer in Australia [12].
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Figure 2.3: Age-mortality for prostate cancer cases in Australia [12].
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2.1.1 Prostate Cancer Detection
Diagnosis of prostate cancer can be done either clinically by prostate specific antigen
(PSA) test, digital rectal examination (DRE) or imaging by transrectal ultrasonography,
or pathologically by biopsy examination. The conventional diagnostic tool of prostate
cancer is digital rectal examination by examining the prostate through the rectum and
feeling any change that may indicate tumour [13].
A blood test is most commonly used to diagnose prostate cancer. Prostate Specific
Antigen (PSA) is a protein produced by prostate gland cells and its increased level in the
blood indicates the presence of prostate tumour volume or other irregularities. A PSA
blood level of less than 4 µg/L is considered normal [14, 15]. PSA is often combined with
a digital rectal examination.

2.1.2 Prostate Cancer Grading and Staging
“Grading” and “staging” are two important factors for assessing the severity and
aggression of prostate cancer.
The Gleason system is the most frequently used grading system for evaluating the
prognosis of men with prostate cancer utilising samples from a prostate biopsy. This
system consists of five grade categories (1-5), each grade is classified according to the
two criteria; glandular pattern and level of differentiation. These two criteria grades are
added together to get a total score out of 10. The majority of prostate cancer patients will
have a Gleason score between 6 and 10 [11].
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The staging system used for assessing the spread of prostate cancer is the Jewett system.
This system uses letters (A, B, C and D) to distinguish staging groups. A is the least
progressed and D is the most progressed [11].
The American Joint Committee on Cancer has created a precise staging system, called
the Tumour Node Metastasis (TNM) system, which consists of four stages, each one
taking into account three factors; tumour extent (T), lymph nodes involvement (N) and
metastases (M). This is a more precise system than Jewett system since these factors have
more subcategories [11].
Grading and staging systems help specify which type of treatment should be used to
overcome the spread of the disease.
2.1.3 Treatment Options
Prostate therapy can be done by different treatment modalities, which depends on the
stage and spread of the disease. These treatments include radical prostatectomy,
chemotherapy, hormone therapy, radiotherapy (external beam therapy, internal
radiotherapy, intensity-modulated radiotherapy and proton therapy) or a combination of
these treatments are among the options available. The choice of the treatment modality
depends on many factors such as a patient’s general health, age, the patient’s choice and
the cancer stage [16].
Prostate cancer patients often have a life expectancy of more than ten years, but this
depends on the treatment options and the disease stage [13].
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2.1.3.1 Radical Prostatectomy
This treatment method involves a completely removing the prostate and seminal vesicles.
Surgical removal is an effective treatment option for small, low stage and localised
prostate tumours [17]. The urethra and bladder are re-attached after the operation of
removing the prostate and any adjacent tissue in which cancer my spread. It effectively
limits the disease spread. Furthermore, prostate removal is not an effective choice for the
large tumour that has spread to the lymphatic system [18]. In addition, incontinence and
impotence problems could occur as a result of removing the prostate gland [19]. Results
of treated prostatectomy patients between 1994 and 1995 revealed the negative
consequences of this treatment, whereby 5.4% of the patients suffered uncontrolled urine
for six months post-surgery, 16.9% had recurrent leakage and 45.6% had unintentional
urinary leakage [20].

2.1.3.2 Hormone Therapy
Hormone therapy is an effective treatment method for late-stage prostate cancer, which
has spread to other body parts. This treatment involves the administration of hormones
that suppress testosterone hormone production, because testosterone stimulate cancer
cells growth and spread [21]. There are several side effects are associated with this
treatment such as body hair loss, libido loss, bone loss, energy loss and weight gain [19].
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2.1.3.3 Chemotherapy
This treatment uses cytotoxic drugs, which are delivered intravenously, orally or cavity
insertion to kill cancer cells. Chemotherapy could be used with other treatment methods
including radiotherapy and before or after radical prostatectomy [21].
2.1.3.4 External Beam Radiotherapy (EBRT)
Radiotherapy aims to treat cancer by utilising ionising radiation for damaging cancer cell
DNA. This damage is caused by double strand breaks (DSB) in DNA, which leads to cell
death. DNA damage occurs through direct action on DNA or indirect action on the
surrounding medium that leads to production of free radicals, subsequently causing
chemical damage to the DNA. The damage DNA by particle radiation is caused by direct
action, while electromagnetic radiation causes indirect action [22, 23]. Radiotherapy is
achieved by delivering the optimal planned radiation dose to well-defined treatment
volume while minimising the delivered dose to the normal surrounding tissues and critical
structures and avoiding any toxicity for these structures [24]. Prediction of the toxicity is
essential to maximise the reliability of the treatment [25]. External beam radiotherapy is
a treatment method which delivers high energy x-rays (6-18 MV). A linear accelerator
(Linac) is used to deliver radiation to the patient from various angles, with multileaf
collimators defining the shape of the radiation field. To localize the target, spare
surrounding healthy tissue, and reduce toxicity, this treatment employs three-dimensional
(3D) tumour visualisation. Volumetric modulated arc therapy (VMAT), intensity
modulated radiation treatment (IMRT), and helical tomotherapy are some other external
treatments [13]. Radiotherapy causes a process known as "mitotic catastrophe", whereby
multiple double strand breaks in DNA are
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unrepairable [26]. Delivering radiation accurately by locating the position and the margin
of the tumour is the most significant aspect of radiotherapy [27].

2.1.3.5 Brachytherapy (BT)
Brachytherapy is a type of radiotherapy that involves inserting or placing small
radioactive sources directly into or adjacent to the target tissue to be treated within the
patient. These radioactive sources provide non-uniform irradiation of the target volume.
Radioactive sources are formed by very tiny pieces of radioactive material, called ‘seeds’
or ‘pellets’. These radioactive materials are used to deliver a specified dose of radiation
to the target using needles, catheters, or applicators. Brachytherapy seeds may be placed
temporarily for a short period or permanently left in the patient’s body to release radiation
over time [28]. With brachytherapy treatment, a large amount of the dose can be delivered
directly to the tumour, while reduction of the dose takes place in the surrounding normal
tissue, according to the inverse square law, which reduces acute and later complications
for these surrounding normal tissues. Brachytherapy is an efficient treatment option for
different types of cancers, including breast and prostate cancers [29].
A transrectal ultrasound (TRUS) guided template is an effective method for accurate
needle positioning and dose distribution in interstitial prostate brachytherapy [30, 31].
BT can be delivered in four modalities with respect to dose rate; high dose rate (HDR),
medium dose rate (MDR), pulsed dose rate (PDR) and low dose rate (LDR) [32]. The
isotopes used for HDR brachytherapy have dose rate >12 Gy.hr-1, while isotopes with
dose rate between 0.4 Gy.hr-1 and 12 Gy.hr-1 are used for LDR brachytherapy. The
treatment results for MDR were poor in comparison with LDR and HDR; therefore, it is
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not in common use [33]. Brachytherapy procedures requires less fractions and shorter
time for treatment, followed by a short recovery time compared with external beam
radiation therapy (EBRT). The following are the four types of brachytherapy implants
that are commonly used:
▪

Surface implant: The source is positioned over the tissue to be treated using molds
or flexible applicators (e.g. superficial tumours of forehead, eye, lip, and penis).

▪

Intracavitary implant: The sources are inserted into a natural body cavity, often
with the help of specially designed applicators that allow for precise source
placement (e.g. cervix, rectum and antrum).

▪

Interstitial implant: External needles or catheters (for temporary or permanent
implantation) are used to insert the sources into the diagnosed tumour (e.g. breast,
neck, urethra and anus).

▪

Intravascular implant: The source is placed inside the artery (e.g. to prevent
restenosis after angioplasty).

There are two main brachytherapy methods used for cancer treatments as follows:
1- Low Dose Rate Brachytherapy (LDR)
This treatment involves permanent implantation of radioactive seeds with low activity (≈
40-70 cGy per sec) into the target volume. The number of seeds differs based on the
treatment location and target volume and may exceed 150 [22]. This treatment lasts until
the radioactive source’s lifetime is over. In this treatment, the most commonly used
isotopes are Iodine-125 (I-125) with a half-life of 59.49 days and Palladium-103 (Pd-103)
with a half-life of 17 days [34].
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I-125 and Pd-103 are emitters of low energy photons with low dose rate delivery. The
overall radiation dose delivered by I-125 and Pd-103 by the time the radioactive source
has completely decayed is approximately 145 Gy [35]. Low dose rate brachytherapy is
more beneficial for low-risk cancer patients and to treat any remaining tumours following
the use of other treatments. LDR is used as a monotherapy for patients with a PSA less
than 10 ng/mL, stage T1b-T2a and a Gleason score less than 6. LDR can also be used in
specific higher/grade patients or conjugate therapy with external beam radiotherapy in
which EBRT course is delivered after LDR seed implantation [29, 35].
Different types of cancer are treated with brachytherapy seeds. Prostate cancer treatment
can be achieved with LDR brachytherapy by placing a large number of seeds throughout
the treated area and allowing them to emit radiation for weeks or months until they
become inactive. The advantage of LDR BT over EBRT is the ability to deliver optimum
high doses to the prostate while saving the surrounding normal tissues. Also, the LDR BT
procedure is faster and has less complications (impotence, bleeding and urinary
incontinence) than prostatectomy [36].

2- High Dose Rate Brachytherapy (HDR)
This treatment involves temporary implantation of radioactive sources with high activity
which deliver dose rates of ≈1 cGy per sec in a well-defined tumour for a short period of
time until a prescribed dose has been delivered [37, 38]. The widely used source in this
therapy is Ir-192 with a half-life of 73.83 days. This treatment is accomplished by
inserting catheters into the target area using one of three methods: placing radioactive
sources in body cavities, surgical insertion, or superficial treatment with wax molds.
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From the positions at which the source stops (the dwell position) and the time it remains
at each position (the dwell time), the dose distribution can be determined. Remote
“afterloading” units are used in modern high dose brachytherapy sources with dose rates
of 100-300 Gy per hour [37]. It is important to have a real visible representation of a
catheter’s insertion with respect to the adjacent anatomical structures and evaluate if the
catheter’s insertion is suitable for treatment. Various imaging systems are available for
different treatment types which include Computed Tomography (CT), Magnetic
Resonance Imaging (MRI), or Ultrasound (US) [39]. To manage the optimum dose
distribution to the target area in the patient, a treatment planning system (TPS) is used to
specify the dwell position and dwell time for each source [40]. After removing the
sources, an HDR patient is not radioactive, in contrast with an LDR patient who still emits
radiation after treatment procedure, due to the remaining low energy source inside the
patient's body [41]. For patients with localized intermediate-to-high risk cancer, HDR
brachytherapy is used as a conjugate treatment with external beam radiotherapy [31]. This
technique allows for maximum sparing of vital organs near the prostate, such as the
rectum, urethra, and bladder, when compared to external beam radiotherapy. The best
dose distribution is achieved by accurate positioning with a modern planning systems and
high dose rate afterloaders for HDR [42]. High dose rate radiotherapy for a prostate cancer
procedure includes insertion of catheters into the treatment area through the perineum
using a fixed template, and transrectal ultrasound for guidance. Examples of template,
catheter, transrectal ultrasound and the setup for prostate treatment are shown in the
Figures 2.4 and 2.5.
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Figure 2.4: An example of a template and catheter system.

Figure 2.5: An example of transrectal ultrasound equipment [43].
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2.1.4 Brachytherapy Sources
The first radioactive nuclides used as a source for brachytherapy were Ra-226 and Rn222, but because of safety issues their use has been discontinued. The most common
radioactive nuclides sources used today are Ir-192, Co-60, I-125, Cs-137, Pd-103, Ru106 and Sr-226; the less commonly used sources are Au-198, Cf-252 and Ru-106. The
physical characteristics of some brachytherapy sources are listed in Table 2.1.

Table 2.1: Physical characteristics of some sources utilised in brachytherapy [44].
Radionuclide

Half-Life

Photon Energy

Half-Value

Exposure rate

(MeV)

Layer (mm lead)

constant
(R cm-2 mCi-1 h-1)

Ir-192

73.81 days

0.38 avg.

2.5

4.69

Co-60

5.26 years

1.17, 1.33

11

13.07

I-125

60.2 days

0.028

0.025

1.46

Cs-137

30 days

0.662

5.5

3.26

Pd-103

17 days

0.021 avg.

0.008

1.48

Ru-106

368.2 days

39 keV (beta)

-

-

Au-198

2.7 days

0.412

2.5

2.38
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2.1.4.1 Iridium-192 HDR Source
The most commonly used isotope source for high dose rate brachytherapy treatment
recently is Iridium-192 (Ir-192) [41]. It is a consequence of a neutron capture process of
stable Ir-191 and a neutron in a nuclear reactor as shown in equation 2.1:
1 0

n + 191Ir

192

Ir + γ

(2.1)

Ir-192 has a half-life of 73.81 days and a high specific activity (maximum 340.98
GBq/mg). Therefore, it can be utilised for temporary implants with an approximate decay
correction of 1% per day. It decays mainly via beta emission (β-) to produce Platinum
(Pt-192) (95.13%) as a daughter nuclide and via electron capture (EC) to produce
Osmium (Os-192) (4.87%). Subsequently, as shown in Figure 2.6, gamma photon with
an average amount of energy (0.38 MeV) is emitted in the process after daughter nuclei
decay to the ground state [42].
HDR Iridium sources used now are cylindrical-shaped in a capsule made of either
stainless steel or thin titanium to avoid any leakage during the process and to provide easy
handling with an afterloading machine. A new source with strength of 10 Ci is used in
the hospitals and needs to be replaced every 3-4 months i.e. when its strength decays to
3-4 Ci.
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Figure 2.6: Schematic diagram of the two different decay schemes of 192-Ir. β- decay of 192-Ir
and EC decay of 192-Ir [41].

2.1.5 Treatment Planning System (TPS)
The aim of the treatment planning is to cover the Planning Target Volume (PTV) with the
prescribed radiation dose as well as conserve surrounding organs as possible. According
to the recommendation of American Association of Physicists in Medicine (AAPM),
TG43 and TG43-U1 formalism is used for dose distribution calculations in modern
brachytherapy treatment planning systems [45, 46]. In this formalism, a brachytherapy
source in a uniform water-equivalent medium is used to verify the measurements either
by Monte Carlo (MC) or Thermoluminescent Dosimetry (TLD) methods. The dose
distribution in and around any radioactive source is calculated by the
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treatment planning system (TPS). The two-dimensional algorithm (TG43) is utilised to
determine the dose rate for each dwell position and the total dose rate is calculated by
adding the dose rates at each of the dwell positions. The next section describes the TG43
algorithm and its parameters.
2.1.6 Dose Calculation Formula (TG43)
The protocol for dosimetry of interstitial brachytherapy sources recommended by the
Radiation Therapy Committee of the American Association of Physicists in Medicine
(AAPM) was published by Task Group Report No. 43 in 1995. In this protocol, the
recommendations for dose calculation formalism, BT source specifications and
calibrations have been defined [45]. A revised AAPM version (TG43-U1) that was
released in 2004 added new sources and made corrections to the formalisation [46]. The
TG43 protocol uses many factors to be taken into account 2D water-equivalent medium
dose measurements for brachytherapy sources, such as air kerma strength, geometry
function, dose rate constant, radial dose function and anisotropy function [45, 46]. These
factors take into consideration source encapsulation, source geometry, the scattering
effect in the water around the source and spatial distribution of radioactivity in the
radioactive source. Since TG43 utilises real measurements in the medium, it has become
one of the important methods for dose rate calculations that are widely used for HDR
brachytherapy. The geometry used for point dose calculations is seen in Figure 2.7, where
the distance between the source centre and the point of interest P(r,θ) is r ( in cm), θ is the
polar angle of P with respect to the longitudinal axis of the source, reference point at r0
= 1 cm and θ0 = 90° and L indicates the active length of a line source.
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Figure 2.7: Brachytherapy calculation geometry used in TG43-U1 formalism.

Since the radioactive seeds used in brachytherapy are cylindrically symmetric, then
radioactive seeds dosimetry is considered in two dimensions. The 2D dose-rate
distribution at a point P(r,θ) is calculated using the following formula:

𝑫(𝒓, 𝜽) = 𝑺𝒌 Ʌ

𝑮˪(𝒓,𝜽)
𝑮˪(𝒓˳,𝜽˳)

𝒈˪(𝒓) 𝑭(𝒓, 𝜽)

(2.2)

Where
-Sk is the air kerma strength: It is the air kerma rate Ḱ (d) in vacuum at a specific
distance (d) multiplied by the square of distance (d2). d is taken to be 1m along the
transverse plane of the radiation source in free space. The unit of Sk is U (1U= 1 µGy m2
h-1).

Sk = Ḱ (d). d2

(2.3)
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-Ʌ is the dose rate constant: It is defined as the ratio of dose rate to water at the reference
point, P(r˳, θ˳) and air kerma strength Sk. The unit of Ʌ is cGy h-1 U-1.

Ʌ=

Ḋ(𝑟˳,𝜃˳)

(2.4)

𝑆𝑘

In a study conducted by The Interstitial Collaborative Working Group (ICWG), dose rate
constants for values can be measured in a solid water medium or achieved by Monte Carlo
Simulation for Ir-192 [47, 48].
-G(r) is the geometry function: This takes into account the variation in relative dose
caused by the radioactivity's spatial distribution within the source [46].

GP(r, θ) =

1
𝑟2
𝛽

for point-source

(2.5)

for line-source

(2.6)

𝑖𝑓 𝜃 ≠ 0°

𝐿𝑟 𝑠𝑖𝑛𝜃

GL(r, θ) =
(𝑟² − 𝐿²/4)¯¹

𝑖𝑓 𝜃 = 0°

Where L is the active length of the radioactive source, β is the angle formed by the active
length to the point of interest P(r,θ), θ is the polar angle of the source relative to the point
of interest P(r, θ).
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-g(r) is the radial dose function: This function considers the reduction in dose rate due
to the attenuation of photons in the medium. According to TG43 report, the radial dose
function is calculated for point and line source by the following formula:

𝑔(𝑟) =

Ḋ(𝑟,𝜃˳)𝐺(𝑟˳,𝜃˳)
Ḋ(𝑟˳,𝜃˳)𝐺(𝑟,𝜃˳)

(2.7)

-F(r, θ) is the anisotropy function: The 2D anisotropy function takes into consideration
the distribution of the dose around the source and the effect of photon attenuation due to
photon scattering and absorption at different angles and distances around the source. F(r,
θ) is determined by:

𝐹(𝑟, 𝜃) =

Ḋ(𝑟,𝜃)𝐺˪(𝑟,𝜃˳)
Ḋ(𝑟,𝜃˳)𝐺˪(𝑟,𝜃)

(2.8)

The value of the anisotropy function along the source's transverse plane is equal to one.
This value decreases according to these criteria:
- As the polar angle (θ) approaches 0˚ or 180˚
- As the radial distance decreases
- As the photon energy decreases
- With increasing encapsulation thickness
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2.2 Overview of Breast Cancer
The breast is the tissue overlying the chest muscles. The female breast is mostly made up
of three main components: lobes, ducts and connective tissue. Where each breast consists
of 15-20 lobes and each lobe contain specialised glands (lobules) that produce breast milk.
The ducts connect lobes and lobules and deliver milk to the nipple. The connective tissue
is formed of fibrous and fatty tissue that surrounds everything as shown in Figure 2.8.

Figure 2.8: Breast Anatomy [49].
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Breast cancer is a disease forms in the breast cells, in which cells lining the breast ducts
or lobules become abnormal and grow out of control to form tumours and may spread to
the rest of the body if not treated. Breast cancer can develop in men and women. However,
it is more common in women and affects a small number of men [50].
Breast cancer is a major health concern for women globally and it is the major reason of
death from cancer in women all over the world. In 2012, almost 1.7 million cases were
diagnosed, with over 500,000 deaths.
In 2019, it was estimated that breast cancer is the most form of cancer diagnosed in
Australia, with 19,371 new cases reported and undergoing diagnosis [51]. Also, the
estimated number of deaths from breast cancer in that year was 3,058 females. Figure 2.9
illustrates breast cancer incidence between 1982 and 2019 in Australia [51].

Incidence of breast cancer in women by year of
diagnosis
22,500

No. of cases

20,000
17,500
15,000
12,500
10,000
7,500
5,000
2,500

Year

Figure 2.9: Female breast cancer incidence in Australia from 1982 to 2019 [51].
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Primary cancer, also called “non-invasive breast cancer”, arise when cancer cells have
initiated in breast lobules or ducts and have not invaded or spread to other tissues.
“Invasive breast cancer” arise when cancer cells spread to healthy tissue surrounding the
breast. “Metastatic breast cancer” occurs as cancer cells in the breast spread to other areas
of the body through bloodstream or lymphatic system. This also sometimes referred to as
“advanced breast cancer” [52].
2.2.1 Breast Cancer Detection
Early diagnosis of breast cancer increases the chances of effective treatment and increases
the chances of surviving. Many women notice breast change symptoms which they can
tell are not the usual “normal”. The “triple test” can then be used to medically investigate
breast changes and it is an accurate method for breast cancer detection. It includes three
steps: providing a medical history, clinical breast examination, then breast imaging by
standard imaging technique such as mammogram and ultrasound or breast biopsy by
removing the tissues or fluids from the suspect area for examination. The biopsy results
reveal information about the tumour size, type, grade, and its boundaries, to determine
the stage of breast cancer. Stages are classified from 0 to IV, with stage 0 for pre-invasive
breast cancer and stage IV for advanced breast cancer. Stages of breast cancer are used to
decide what treatment options should be used.
2.2.2 Types of breast cancer treatment
There are many kinds of breast cancer treatment. The recommendation about the type of
treatment chosen is determined by a number of factors, including the type of tumour, its
size, and the patient's age.
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2.2.2.1 Surgery
This treatment can be done either by partial removal of the tumour and its surrounding
tissue from the breast which is called a lumpectomy, or the removal of the whole breast
which is called a mastectomy.
2.2.2.2 Chemotherapy
This treatment uses drugs to kill and destroy cancer cells. These powerful medicines
reduce the spread of the cancer cell to the other body parts and prevent the growth of the
cancer. This type of treatment can cause side effects, such as hair loss, hot flushes, nausea,
fatigue and menopause.
2.2.2.3 Hormone therapy
This treatment uses drugs to inhibit hormones, like estrogen and progesterone, from
increasing the breast cancer cells growth. It is frequently utilised after surgery to decrease
the risk of cancer returns or it is sometimes used before surgery to reduce the volume of
the tumour for total cancer removal. It is also helping to slow or stop the growth of a
spreading cancer. This type of treatment can cause side effects, like fatigue, nausea, hot
flushes, muscle pain and vaginal discharge or dryness.
2.2.2.4 Radiotherapy
Radiotherapy, sometimes referred to as radiation oncology or radiotherapy, is a form of
treatment that involves the use of radiation doses to destroy cancer cells or remnants of
cells that may be left in the affected body region (breast, chest or armpit) after surgery.
Radiotherapy is usually given following chemotherapy treatment [53]. The 1990 National
Consensus Development Conference announced that “lumpectomy and radiotherapy
should be considered as the preferred treatment for this disease management”. Many
studies agree that post-operative radiotherapy is proven by a number of randomised
clinical trials to decrease the risk of recurrence of breast cancer following lumpectomy
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[54-56]. Radiotherapy plays a significant role in the breast cancer treatment either as a
post-operative adjuvant treatment or as mitigation for advanced cancer. It has been
demonstrated that it improves local control and survival and is widely used in Australia,
the United Kingdom and the United States for 24-71% of breast cancer patients [57, 58].
A study conducted by Delaney et al. estimated that 83% is the optimum ratio of breast
cancer patients who can be expected to receive radiation treatment as part of their breast
cancer management [59].
A variety of different radiotherapy modalities are used to treat breast cancer. External
beam radiation therapy (EBRT) is the most widely used radiation modality in the
treatment of breast cancer. A machine known as a linear accelerator (LINAC) is used in
EBRT to deliver a high radiation dose of x-rays from outside the body to the breast [60].
In addition, there are many forms of external beam radiotherapy such as intensitymodulated radiotherapy (IMRT), 3-D conformal radiotherapy (3D-CRT), and proton
therapy [61]. Other methods include internal beam radiotherapy or brachytherapy, which
involves placing a radioactive source directly into the tumour using multiple needles [62].

2.3 Skin dosimetry
In the human body, the skin is the largest organ. Epidermis, dermis, and hypodermis are
the three primary layers of the skin. as shown in Figure 2.10. The outermost protective
layer of skin is the epidermis; in the epidermis the innermost layer is the basal layer that
has the ability to produce new cells that elevate the older cells to the body surface as dead
cells. The thickness of epidermis layer varies from approximately 0.04 mm in the eyelid
to 1.5 mm in the base of the foot. The thickness from the surface to the basal layer also
varies in different body parts. The average thickness is approximately 0.07 mm [63, 64].
Beneath the epidermis is the dermis which contains sweat glands, blood capillaries, nerve
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ending and hair follicles, followed by the hypodermis which is the deepest layer that
contains connective tissue and fat.

Figure 2.10: Structure of the skin [65].

The skin is extremely sensitive to radiation, and the epidermis and its basal layer located
at a depth of approximately 0.07 mm beneath the skin surface is the most sensitive part
of the skin. This is known to contain the most radiosensitive epithelial cells as noted in
ICRP publication “The biological basis for dose limitation in the skin” [66]. The basal
layer of the epidermis reacts with radiation and leads to undesirable skin complications.
In order to measure the skin doses precisely, a dosimeter that is small and flat enough to
determine the radiation dose delivered to the basal layer of the epidermis is required.
During ionising radiation treatment, the skin is at risk for many effects such as erythema,
desquamation, and necrosis [67, 68], therefore it is important to assess the potential early
and late impact of the treatment. Several studies indicate that there is a relation between
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the induction of basal-cell carcinoma (BCC) and radiotherapy [69, 70]. Many clinical
studies in radiotherapy have shown that the exposure of the skin is influenced by the
treatment technique used during external beam radiotherapies such as the use of
immobilisation devices, blocks, trays and wedges [67, 71-73].

2.4 In-Vivo Dosimetry (IVD)
In-vivo is Latin for “in living organisms”. In-vivo dosimetry is a method of measuring
the real dose received by a patient during treatment, which allows comparison of the
delivered dose and the prescribed dose to ensure accuracy within acceptable limits [74].
With the improvement of different complex modalities of radiation treatments, in-vivo
dosimetry procedures (IVD) have become an important and effective method to measure
the actual dose of radiation administered to the patient during treatment. IVD is regarded
as an essential quality assurance tool. It provides many benefits such as real-time dose
measurement, immediate detection of any variation in dose measurements, detection of
systematic errors during the treatment session, avoiding radiotherapy misadministration
and allowing direct intervention and error correction during treatment [75]. The ultimate
aim of a radiation treatment plan is to deliver maximum radiation dose to the tumour and
minimum radiation dose to the surrounding normal tissues and organs at risk such as skin,
rectum, bladder or urethra. The optimal benefit of radiation treatment is achieved by the
accurate delivery of radiation dose to the patient. In general, in-vivo measurements
provide an extra safeguard for radiotherapy procedures. In-vivo dosimetry is considered
a part of quality assurance of a radiotherapy treatment. The use of in-vivo dosimetry has
become more common according to the recommendations of the World Health
Organization (WHO), the International Atomic Energy Agency (IAEA) and the
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International Commission on Radiological Protection (ICRP) [76-78]. In-vivo dosimetry
procedures in EBRT, can be conducted on the surface of the patient’s body to measure
skin dose, entrance dose, and exit dose. The International Commission of Radiation and
Measurements (ICRU) provides recommendations regarding the delivery of radiation
dose, indicating that the radiation dose to be delivered should be limited to within 5% of
the prescribed dose. It is therefore advised that the total error in the delivered dose should
be less than 5% at the end of the treatment [79].
The in-vivo dosimetry procedure in brachytherapy (BT) can be performed by placing a
dosimeter near or inside the target or volume to be checked for evaluation of dose
delivered during treatments. According to ICRU recommendation 24 (1976), in-vivo
dosimetry includes measurements of external (entrance, transmission and exit) doses and
measurements of internal cavity absorbed doses. In-vivo dosimetry can also perform a
maximum effective delivery check of the radiation dose [80].
Many organisations such as the American Association of Physicists in Medicine (AAPM)
and the European Society of Therapeutic Radiology and Oncology (ESTRO) recommend
in-vivo dosimetry to play a role in the improvement of patient care in radiotherapy. Invivo dosimetry is well proven for use in EBRT [81], but additional complications may
emerge when applied to HDR brachytherapy. Table 2-2 introduces the important aspects
of in-vivo dosimetry and the many advantages that state-of-the-art brachytherapy systems
may have [82].
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Table 2.2: Important aspects of in-vivo dosimetry (IVD) and their main advantages [82].
Essential aspects
for

Aim

Existing developments

Further developments

dosimetry

Dose monitoring; error
detection; QA of treatment
plan; dose escalation
control

Dose monitoring; gross
error detection

Improvement of
dosimetric accuracy of
IVD in target/OAR

Sterilization

Eliminate risk for infection

In-house solutions for
sterilization of catheters
that contain dosimeter
probes

Integrated IVD catheters
in source applicators and
IVD catheters dedicated
for specific anatomical
sites

Spatial accuracy

Fixate dosimeter with
respect to target, OAR or
source applicator; stabilise
anatomical region;
maximize dosimetric
accuracy

Dosimeter probes
embedded into
endorectal balloons

Develop specialised
equipment for specific
anatomical sites

Identification of
source

Error detection; geometric
feedback for
brachytherapy source;
facilitate independent
catheter reconstruction

Multipoint dosimeters

Investigate full in-vivo
potential; optimize and
adapt various existing

IVD
Target/OAR

Position

Identification of
dosimeter
Position

Validate calculated
reference dose rates;
identify target, OAR or
source applicator
movements; geometric
feedback for dosimeter;
QA of treatment planning
system

algorithms
Further in-vivo
Detector positioning
technology; adaptive
error detection algorithm

performance studies

Reconstruction
Statistical error
criterion

Automation

Improve sensitivity and
specificity for error
detection algorithms

Comparisons between
measured and planned
dose rates or source
positions, considering all
known sources of
uncertainty

Thorough sensitivity and
specificity assessments;
further studies of
uncertainties for IVD

Minimize resource
requirements and
interference with clinical
workflow

Non available

Afterloaded dosimeter;
communication line
between afterloader and
IVD system
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The most employed detectors for in-vivo dosimetry are thermoluminescent dosimeters
(TLDs), scintillators, radiochromic films, diamond detectors, semiconductors and metaloxide semiconductor field effect transistors (MOSFETs) [83]. The advantages and
disadvantages of different types of dosimeters utilised in brachytherapy are listed in
Tables 2.3a and 2.3b.
Table 2.3a: Advantages of different types of in-vivo dosimeters utilised for brachytherapy [82].

TLD

Semiconduc MOSFET

Diamond

Scintillator

Small size

tor
Produced in

Small size, can be

Small physical

High sensitivity

various forms

used in small fields

size

and accuracy

(powder, chips,

and steep dose

rods, ribbons)

gradients

Linear response

Instant readout

Small sensitive
volume
Insignificant

Instant readout,

over a wide range

Real time readout

directional

good

of doses

variation in dose

reproducibility

response

and long-term
stability

Not expensive

High sensitivity

Little beam

Tissue equivalent

perturbation

Linear response to
dose

Reasonably tissue

Good mechanical

Permanent dose

Water resistant

Almost tissue

equivalent

stability

storage

Simple to use

Simple

Simple

Resistant to

Dose rate, energy

instrumentation

instrumentation

radiation damage

and temperature

equivalent

independence
Good spatial

High spatial

Plane energy

High spatial

resolution

resolution

response

resolution
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Table 2.3b: Disadvantages of different types of in-vivo dosimeters utilised for brachytherapy
[82].

TLD

Semiconductor

MOSFET

Diamond

Scintillation

No instant

Periodical calibration

Bias voltage

High coast

Need to prevent

readout

connection

background signal

required

from primary beam

Energy

Have temperature,

Temperature,

Slight dose rate

To achieve light

dependent and

energy, dose rate and

energy and

dependence

transmission to

sensitivity

directional dependence

directional

detector by optical

dependent

fibre connection

depth
dependent
Need

Require connecting

calibration

cables

Limited lifetime

Large size

before each use
Need pre and

Spatial care needed to

Slight loss of

post irradiation

ensure stability of

charge after

annealing

response

irradiation

Signal erased

Non- linear dose

during readout

response

During prostate HDR brachytherapy, it is important to use a rectal dosimetry system to
measure the dose to the anterior rectal wall due to the rectum being close to the treatment
site (organ at risk) and hence the rectal wall receiving the highest dose during prostate
treatment. Real time monitoring of delivered dose reduces the probability of rectal
complications by stopping, or correcting, the treatment if the measured dose is more than
the predicted dose, in addition to limiting the escalation of dose error for the other
treatment sessions. Rectal dose can be measured in a short time after starting treatment
and a comparison with the calculated dose can be done to ensure that the treatments are
carried out as they were planned.
The Radiation Therapists Oncology Group reports that the expected symptoms of rectum
complication after irradiation are bleeding, cramping, diarrhoea, mucus loss and frequent
toilet trips, which impact negatively on patient life [84]. Dose misadministration can
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occur due to human errors or equipment malfunction, therefore, measuring the actual dose
received by the organ is important for minimising the risk of an overdose to critical organs
[85].

2.5 Silicon Diodes
Semiconductors have been utilised for a long time, with the first in-vivo clinical
experiences introduced by Parker et al. in 1969 [86] and later Inoue et al. in 1979 [87]. A
review of silicon diode dosimetry was published in 1982 by Dixon and Ekstrand [88].
Semiconductor detectors exhibit significant benefits, such as rapid response, ruggedness
and small physical size compared with other dosimeters [89]. Silicon diodes can be made
of either n-type or p-type silicon. A Si semiconductor with extra electron species is known
as an n-type semiconductor, while Si semiconductors with extra holes are known as ptype semiconductors. Typically, a pure silicon crystal (intrinsic) has the same number of
free electrons and holes. The type of impurities added to silicon crystals determines the
type of semiconductor as shown in Figure 2.11. The process of adding impurities is called
doping [90, 91]. Silicon is located in group IV in the periodic table. Adding to the pure
silicon an impurity from group V (a donor element), which has five valence electrons,
leads to increases the number of free electrons (majority electrons and minority holes)
which produces n-type silicon. In a similar way, adding an impurity to the pure silicon
from group III (an acceptor element), which has three valance electrons, leads to increase
the number of holes (majority holes and minority electrons) and results in p-type silicon
[90, 91]. The most commonly-used impurities are phosphorus from group IV and boron
from group III. The intrinsic, p-type and n-type silicon energy levels are illustrated in
Figure 2.12.
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Figure 2.11: Silicon atomic structure for intrinsic, n- and p-type doping [92].
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Figure 2.12: The Band diagram of electron energy for intrinsic, p-type and n-type silicon [93].

The “P-N junction” is one of the key concepts for semiconductor detectors and it is widely
used for dosimetry applications [94]. A p-n junction is formed when p-type and n-type
semiconductors are joined together as shown in Figure 2.13. This junction behaves in
different way than it does with either n or p type separately. The p-type semiconductor
has a high concentration of holes (positive charge). The n-type semiconductor has a high
concentration of free electrons (negative charge). At the p-n junction, the majority carriers
from each side diffuse to the opposite side, which forms a depletion layer of thickness
between 10 µm to 5 mm, a potential is generated and a permanent electric field result
[95]. As ionising radiation passes through the depletion layer, the radiation source's
primary or secondary particles are absorbed, resulting in electron-hole pairs. These
carriers diffuse across the depletion layer and charges which are proportional to the
deposited energy from the ionisation process can be measured through the generated
current [95].

40

Figure 2.13: Schematic diagram of P-N junction diode used as radiation detector [96].

Silicon radiation detectors (Si) have advantages, including being able to measure doses
instantaneously. The high density of silicon compared with water (2.33 g/cm2 vs. 1.00
g/cm2) results in increase in radiation sensitivity to low energy photons. The average
amount of energy required to form an electron-hole pair is 3.6 eV while 35 eV is required
to create ion pairs in an ionization chamber and 300 eV is essential to generate one
electron at the cathode of a photomultiplier in scintillation detector. Thus, a higher
number of charge carriers (approximately 10 times) deposited in the detector for a certain
energy results in a smaller sensitive volume, good spatial resolution, absence of bias
voltage and small overall instrumentation. In addition, a steep dose gradient in high dose
rate brachytherapy required high spatial resolution to analyse dosimetry problems [97,
98]. Energy dependence of the detector response is a property of silicon diodes. This
property originates due to the increase probability of a photoelectric process for low
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energy photons in high atomic number materials, which leads to an over-estimation of the
absorbed dose a in low energy photon fields (eg: 150 keV) [88]. The sensitivity of n & p
type detectors after pre-irradiation was examined by Osvay and Tarczy who determined
that p-type detectors have high resistance for radiation sensitivity change compared with
n-type ones [99]. In general, the instantaneous dose rate dependency of n-type diodes is
higher than that of p-type diodes [100]. Diode radiation detection depends on the dose
rate and the accumulated dose. The diode detector sensitivity reduces with accumulated
dose, since radiation dose produces defects in the semiconductor and thus creates more
recombination centres and traps [101]. Diode currents generated by heat and light is
regarded as “leakage current”. Both leakage current and diode current that is generated
by radiation are temperature dependent. The sensitivity of the diode detector’s increases
with increasing temperature as reported by Grusell et al. [101]. N-type epitaxial silicon
diodes were developed by the Centre for Medical Radiation Physics (CMRP) and are used
for in-vivo dosimetry as a semiconductor detector in this project. Due to various
advantageous properties, such as relatively small sensitive volume and increased radiation
hardness, silicon epitaxial diodes are being used as an alternative to conventional silicon
detectors.

2.6 CMRP Silicon Detectors
2.6.1 P-type epitaxial diode
This diode was designed by the Centre for Medical Radiation Physics at the University
of Wollongong, as a part of Quality Assurance to be used in External Beam Radiation
Therapy. It was manufactured by the SPO-BIT Detector Ltd., Ukraine. In a study
performed by Espinoza, the diodes structure consists of 420 μm p+ substrate layer with a
resistivity of 0.001 Ω.cm and an impurity concentration of 1020 /cm3 and a 50 μm p-type
epitaxial layer having a resistivity of 100 Ω.cm with an impurity concentration of 1014
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/cm3. These two layers are separated by a 2 μm silicon dioxide (SiO 2) layer. Two types
of the detectors were used in this thesis research: one without a guard ring and the other
with an n+ guard ring as see in Figure 2.14.

Figure 2.14: The structure of silicon epitaxial diode (a) with guard ring (b) without guard
ring.

In this study two types of silicon epitaxial diode (with and without guard ring) were
characterised, through investigating its electrical properties (I-V and C-V characteristics),
its charge collection efficiency and its performance under clinical applications, also to
assess the appropriateness of using this detector as a dosimetry in IMRT quality
assurance. The results of this study show the suitability of the epitaxial diode without the
guard ring to be used as a dosimeter in external beam radiotherapy [102]. Aldosari, et al.
[104], investigated the use of p-type epitaxial diode detector which is developed at the
Centre for Medical Radiation Physics (CMRP) in quality assurance for external beam
radiotherapy (EBRT). The diode structure consists of 350 μm p+ substrate layer has a
resistivity of 0.001 Ω.cm and 50 μm p-type epitaxial layer has a resistivity of 100 Ω.cm
with 0.6 x 0.6 mm2 as sensitive area. The detector had a 5 μm overlap of the frontal
aluminium contact layer of n+ and p+ junctions above the oxide layer as shown in Figure
2.15. The aim of this study is to characterise the detector and examine its stability and
radiation hardness in quality assurance for medical applications. The findings were
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compared to a Sentaurus TCAD (Synopsys, Bulgaria) simulation model of the device to
gain a better understanding of the silicone diode's radiation damage mechanism [103].
The preirradiation of epitaxial diode was 40 kGy on a Co-60, the detector response
stabilisation within 5% after irradiation by Co-60 with 120 kGy of gamma irradiation
dose, which reflects a good charge collection efficiency with accumulated dose [104].

Figure 2.15: P-type epitaxial diode structure [104].

2.6.2 Edgeless detector
Silicon detector used in medical dosimetry has limitation regarding its angular
dependence of response because of to its geometry, incident beam energy and back
scattering occurs from the patient or phantom [105], which leads to raise the uncertainty
of the dose estimation. The edgeless detector is a new silicon-detector design developed
in the Centre for Medical Radiation Physics (CMRP) at the University of Wollongong to
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overcome the uncertainty of silicon dosimeters by reduces their angular dependence
[106]. The single edgeless detector manufactured by using two silicon substrates n-type
and p-type of thicknesses 100 μm and 500 μm with two detector sizes 1 x 1 mm2 and 500
x 500 µm2. Either P+ implanted on the top side and N+ at the back side and lateral edges
or N+ implanted on the top side and P+ at the back side and lateral edges as shown in
Figure 2.16. Four different edgeless detector geometries were used (PP-NN-NP and PN).
The existence of three-dimensional junction leads to improve the charge collection
efficiency of in the passive mode of the detector. The edgeless detectors characterised by
assessing their electrical characteristics (I-V and C-V) and evaluating their performance
under clinical conditions (angular dependence, percentage depth dose (PDD), and output
factor (OF) in external beam radiotherapy to specify the detectors’ constancy to be used
in medical dosimetry. The angular dependence of the edgeless detector present good
results that clearly show that the detectors have a potential importance in the clinical
conditions as angular-independent detectors. The percentage depth dose (PDD) results of
the edgeless detectors showed a good consent with ionization chamber for all depths used
in the study. The relation of edgeless detectors with field size has been assessed by an
output factor (OF) test and its results agreed with EBT3 film in small field sizes and
showed slightly larger contradiction at larger field sizes.
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Figure 2.16: The structure of different types of edgeless detectors.

2.7 Monte Carlo Simulations (MC)
Monte Carlo is a computational program for simulating statistical processes [107]. It
depends on repeated random sampling and quantifying physical variables to attain
numerical solutions. MC simulations are known to be the most precise method used in
predicting a dose distribution due to an incident photon beam [22].
Monte Carlo allows us to predict the energy deposited by the particles as well as the
trajectories of each individual particle. Monte Carlo also allows recording the probability
of distribution of possible interactions and their energy deposition. The interest in using
Monte Carlo simulation techniques has increased in different medical physics aspects
such as radiotherapy, diagnostic radiology, nuclear medicine, etc [108]. Monte Carlo is
an important method to calculate accurate dose for brachytherapy treatment planning
system. Brachytherapy need precise dose calculation so that maximum dose can be
delivered to the tumour target without causing excess damage to the surrounding healthy
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tissues. For this study, Monte Carlo is an effective method as it helps for a better
understanding in the calculation of dose. An example of algorithm used for Mont Carlo
simulation for the interaction of gamma rays with matter in a study done by Arqueros et
al. is represented in Figure 2.17.
Monte Carlo applications in brachytherapy was started in the early 1980s. A study by
Williamson and Li [109] developed advanced Monte Carlo code for photons. The dose
distribution around brachytherapy sources in this study was calculated using Monte Carlo
code. The study found that there were many differences in the data compared with the
existing data. The basis of brachytherapy dosimetry protocol is derived from this study
and other similar calculations [45]. It has been proven that the accuracy of Monte Carlo
method is within 2-3% [108]. Monte Carlo simulation was utilised in this thesis to obtain
the dose distribution of Ir-192 radioisotope as brachytherapy source.
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Figure 2.17: Flow diagram of simulation algorithm for gamma rays through matter [110].
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A lot of Monte Carlo simulation codes have been created and used effectively for
simulation of radiation sources in radiotherapy and medical physics applications, such as;
• GEometry ANd Tracking platform (GEANT4) [111],
• NRC’s electron gamma shower software tool (EGSnrc) [112],
• PENetration and Energy LOss of Positron and Electron in matter (PENELOPE)
[113],
• Monte Carlo N-Particle Transport Code (MCNP6) [114] and;
• BEAMnr user code based on EGSnrc [115].
It has been approved by many researchers that Monte Carlo simulation is an accurate
computing method, in which sufficient algorithms for electrons and photons are used
[109, 116, 117].
2.7.1 Limitations of Monte Carlo method
The limitation with Monte Carlo simulation is the long time required to generate and
compute millions of particles, where a large number of particles is necessary, to reduce
any uncertainties to acceptable limits [118]. Geant4 is the Monte Carlo code used for this
thesis to obtain the dose distribution.

2.8 The GEANT4 Toolkit
The Geant4 (Geometry And Tracking) open source C++ toolkit is a general-purpose
Monte Carlo code for the simulation of various particles interaction (such as neutrons,
protons, pions etc) with matter [119]. It was developed by European Organization for
Nuclear Research (CERN) [111]. Geant4 code is capable to describe the interaction of
all types of particles in a medium for a range of energies between a few eV and TeV.
GEANT4 can address various domains of simulation: geometry and material description,
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event and track management, material and field, run, particles tracking within any
geometry, a large number of different physics processes over a wide energy range,
response to particle interactions, user interface and visualization. By simulating many
events with a randomized outcome, Geant4 provides a solution that cannot be computed
analytically. Now Geant4 and EGS are the only open-sources, free and general Monte
Carlo code for radiation physics researches. Its success in this field is evident through its
ability to offer many complementary and alternative physics models that describe both
the electromagnetic (standard electromagnetic and low-energy electromagnetic) and
hadronic (string models and parameterised) physics interactions. It also describes
homogeneous and heterogeneous materials [120].
2.8.1 Components of Geant4
The foundation of the toolkit is the package category. It obtains the global package that
covers units, constants and numerics. There are also materials, particles, graphical
representations and geometry packages. These include the volume, description and
geometry of the detector and the behaviour of the particles in the detector model. A run
package which is a collection of events that are produced according to the same detector
condition and physics processes settings. Event, where the primary particles are
processed. Tracking allows us to track the particle within its environment. And the
visualisation provides a snapshot of the geometrical volumes, particle trajectories, its
physical quantities and its interactions by using different graphic systems [120]. The
major class categories of Geant4 are shown in Figure 2.18.
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A Geant4 simulation contains the following aspects:
•

Specified the particles to be used,

•

Definition of the involved materials,

•

The system geometry,

•

Sensitive detector components and response are specified,

•

The primary events are generated,

•

Storage process of tracks and events,

•

The physical operations governing particles interactions,

•

Definition of the external electromagnetic fields,

•

Tracking particles in the matter and external electromagnetic fields,

•

Event data generation,

•

The visualisation of the detector and particle paths.
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Figure 2.18: The top-level category diagram of the Geant4 toolkit [120].
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2.9 Conclusion
Prostate cancer is the second most commonly diagnosed cancer in men in Australia, and
the third most common cause of cancer death [121], with 25,000 cases predicted to be
diagnosed annually by 2020. Brest Cancer is the most common form of cancer affecting
women in Australia. It is predicted that 19,998 women will be diagnosed with breast
cancer by 2020 [122]. Radiotherapy plays an important role treatment of prostate and
breast cancers. High dose rate brachytherapy, which is usually used in conjunction with
other treatment modalities, is one of the most common treatment options for this disease.
Several studies have shown that the radiotherapy helps both survival rates, and improved
local cancer control. At a recent time, many in-vivo dosimeters have been used to measure
the dose of the skin. The key issue with the current in-vivo dosimeters in precise skin
dosimetry is their ability to measure the dose at a small water equivalent depth and to
have a very thin sensitive volume that allows measurement of the dose in a steep dose
area at interfaces. Silicon diode detectors could be a good choice for the development of
a new in-vivo skin dose measurement technology in real-time.
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CHAPTER 3: Description of the Instrumentation

3.1 Introduction
This aim of this chapter is to thoroughly describe the detectors and supporting equipment
that were proposed and utilised in this thesis, in particular the new n-type epitaxial skin
diode and MOSkinTM. It also describes the electronic readout systems used. Different
human tissue-equivalent “phantoms” used will be also described in this chapter. It also
introduces the experimental field arrangements.

3.2 Detectors
3.2.1 N-type epitaxial skin diode
Silicon diode detectors became popular to be used as in-vivo dosimeters. The main benefit
of diodes is that measurements can be made with it and it gives an immediate checking
of the received dose. Other advantages of diodes include high sensitivity, good spatial
resolution, small size, simple supporting instrumentation, no bias voltage, ruggedness,
and independence from changes in air pressure.
A new type of epitaxial skin diode detector was designed in the Centre for Medical
Radiation Physics (CMRP), at the University of Wollongong, Australia, for utilise in
external beam therapy (EBT) and brachytherapy (BT) in-vivo dosimetry. These new
epitaxial skin diode detectors were fabricated by the facility in SPO-BIT Detector
(Ukraine). An epitaxial-growth technique was used to grow the diode [123]. Epitaxial
layers in silicon detectors have advantages over conventional bulk silicon detectors by
limiting the sensitive volume to a few microns, this is useful for dose measurements in
areas with a steep dose gradient. In addition, epitaxial layers limit the impact of variation
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in diffusion time of irradiation damage and promote more stability with accumulated
dose. Thus the device becomes more radiation-hard [124]. The n-epitaxial layers are 6.5
μm thick, grown on top of a 380 μm n+ thick silicon substrate. The dimensions of the
diode are 2 x 2 mm2 with 1 x 1 mm2 as the central sensitive area. On top of the epitaxial
layer, a silicon oxide (SiO2) layer with a thickness of 0.7 µm and a width of 20 µm is
grown. The SiO2 layer allows selective implantation of the p+ area and also provides
protection for the skin diode. The SiO2 layer was grown by a wet oxidation mechanism
at a high temperature (900-1200 °C) [125] .
The front Aluminium layer of the detectors is 0.7 μm thick with 5μm overlap over the
oxide layer. A schematic diagram of the skin diode structure is shown in Figure 3.1. The
n+ substrate layer has a resistivity of 0.001 Ω.cm and it has an impurity concentration of
1019 /cm3, while the epitaxial layer resistivity is 100 Ω.cm and it has an impurity
concentration of 1013 /cm3 [126]. A “Drop-in” technique was used to embed the diode in
two Kapton pigtail designs one of 0.6 x 10 mm2 cross section, and the other one of 0.16
x 3 mm2 with both have a total length of 320 mm as shown in Figure 3.2. The Kapton
material has an insignificant effect on the measurement of the dose. Kapton's effective
atomic number is 6.6 and a density of 1.42 g cm-3 [127]. This technique is used to reduce
the energy dependence of the diode instead of the high Z materials typically used for
packaging silicon diodes. In addition, this technique reduces the associated intrinsic
angular dependence during the packaging process [128]. More details about the drop-in
technique can be found in another study by Petasecca et al. [129].
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(a)

(b)

Figure 3.1: Schematic diagram of an epitaxial skin diode (not to scale) (a) cross-section view (b)
top view.

The thickness of the build-up material used above the dosimeter sensitive layer is
repeatable and has already proven to have a WED of 0.07 mm as shown in Figure 3.2. A
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thin aluminium foil (0.07 mm) is used to shield the Kapton pigtail outside of the diode,
which is grounded to depress radio frequency interference. These skin diodes were
operated in passive mode (unbiased) to minimise the generation of leakage current.

Figure 3.2: Skin diode on Kapton pigtail shielded by aluminium foil.

Figure 3.3: Sensitive volume covered by Kapton.

3.2.2

MOSkins

MOSkin detectors are a new packaging of MOSFET- detectors developed and designed
by the Centre of Medical Radiation Physics (CMRP) at the University of Wollongong
(UOW), Australia. MOSkin detectors were designed particularly to measure dose at the
skin/air interface for EBXT [130] and hence used for measuring the radiation doses in
both brachytherapy and external radiotherapy. The major difference between MOSFET
and MOSkin is the packaging of the circuit “chip”. In conventional MOSFETs, the chip
is positioned on the top of a substrate enclosed by a bubble epoxy resin. The MOSFET
chip in MOSkin detector sit under the substrate surface and the organic coating above
them is very thin as shown in Figure 3.4. The MOSkin detector is composed of a pMOSFET device with a very small sensitive volume. The thickness of its gate oxide is
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0.55 μm, allowing for very high spatial resolution in dose measurements of high dose
gradient regions [130, 131]. A full MOSkin detector is 0.4 mm thick, 3 mm wide and,
330 mm long [132].
(a)

(b)

Figure 3.4: Simplified diagram a) MOSFET detector b) MOSkin detectors [133].

To make a MOSkin detector, a MOSFET chip is dropped into a thin layer of a flexible
polyimide film carrier by the “drop in” technique. This Polyamide film prevents any harm
or damage to MOSkin electronics, protects electronics from moisture, provides electrical
connection to the chip and prevents any direct contact between the detector and patient’s
body. A thin layer of Kapton build-up material surrounds the chip. Over a wide
temperature range, Kapton polyimide film retains its physical, mechanical, and electrical
properties [134]. The Kapton layer provides an effective equivalent depth of
approximately 70 μm in body tissue

[132]. This depth is consistent with the

recommendations of the international commission on Radiation Units & Measurements
for skin dosimetry (ICRU) [135, 136]. Also, Kapton is relatively insensitive to radiation
damage [137]. A study made by Zahra [138] showed the MOSkin detector to be suitable
for use as a reliable real-time dosimetry device. In this study, it was proven that the
MOSkin detector has been made to be effectively temperature-independent and can be
used as a dosimeter for surface and at-depth dose measurements.
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3.2.3 Radiochromic Film
Radiochromic film is widely used as a radiation detector in radiotherapy by measuring
the change in its colour after exposure to ionising radiation due to the energy transfer
from the incoming photons. Its excellent planar spatial resolution (<25 µm), low spectrum
sensitivity, near tissue equivalency, low energy independence, insensitivity to visible
light, and ability to self-develop make it ideal for dosimetry. The Gafchromic EBT 3
radiochromic dosimetry film is made up of a single active layer that is 27 m thick and
contains the active component, as well as marker dye, stabilisers, and other additives that
give the film its low energy dependence. The active layer is placed between two 120 µm
clear polyester substrates, which eliminates the need to keep track of which side of the
film is facing the scanner's light source. The yellow marker dye reduces UV/light
sensitivity when used in conjunction with an RGB film scanner. EBT3 film was used in
breast HDR brachytherapy treatment.

3.3 Phantoms
Different tissue-equivalent “phantoms” were used throughout this project to mimic the
radiological characterisation of the human body: solid “water” phantoms, CIRS
ultrasound prostate phantom, rotatable cylindrical phantom and CIRS IMRT Breast
phantom. Given that the amount of water in the human body is approximately 75%, water
is the best substance to mimic the absorption of the radiation dose in the human body but
water itself would create some difficulties like how to assure waterproofing of the detector
and how to position the detector in the water. Therefore, new materials (solid waterequivalents such as PerspexTM Polymethylmethacrylate (PMMA)) were developed, which
have similar radiation absorption and scattering properties to water. Solid waterequivalents show similar electron density, attenuation coefficient, effective atomic
number and radiation-absorption properties to water. In addition to its properties, solid
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water-equivalent phantoms have been approved by the medical physics community as a
suitable surrogate for water due to their easy setup and dismantling [139, 140]. The solid
phantom slabs that were used for HDR BT in this project have a size of 9 x 9 cm2, with
different thicknesses of 0.5 cm, 1 cm, 2 cm and 3 cm. Two PMMA phantoms were used
for EBRT in this project. One of the phantoms has a size 30 x 30 x 1 cm3 which is used
in PDD, output factor, energy dependence and dose per pulse experiments measurements.
The other phantom has a size 24 x 17.5 x 5 cm3 and is used in the angular dependence
experiments where it was inserted into the rotatable cylindrical phantom used for the
study as shown in Figure 3.5.

Figure 3.5: PMMA slab phantom and board.

The breast phantom used for HDR BT was constructed of aqueous gel using a breast
mould to provide the shape of real breast. The preparation of the phantom was done by
adding 1 tablespoon of gelatine powder for every 100 ml of water up to the required total
amount, then storing the phantom in a fridge for several hours till gelation was complete
to yield a “solid” realistic phantom. The breast phantom has dimensions of 6 x 17 x 30
cm3 approximately. Figure 3.6 shows the breast mold used and the resulting beast
phantom. Gelatine was used for forming this medical phantom, due to the resultant gel’s
similarity to human tissue response for incident gamma rays. The density, ρ, is 0.976 ±
0.012 gm/cm3 for aqueous gelatine gel and 1.00 gm/cm3 for water.
60

Figure 3.6: Breast mold and resultant breast tissue “phantom”.

3.3.1 CIRS Ultrasound Prostate Phantom
For the prostate study, a CIRS tissue equivalent ultrasound prostate phantom was used in
this project. This phantom was developed by Computerised Imaging Reference System,
Inc. The phantom includes important structures such as prostate, rectum, urethra, seminal
vesicles and perineal membrane. The CIRS phantom is made of a Zerdine gel formulation.
Zerdine is a good substance for a prostate phantom because it has s density and atomic
number comparable to soft tissue [141]. It was designed specifically for imaging
phantoms during CT, MRI, ultrasound and elastography. The material was made based
on liver tissue; all structures are contained in a clear acrylic container with dimensions
11.5 x 7.0 x 9.5 cm3 as shown in Figure 3.7. A 3 mm simulated perineal membrane enables
needle insertion inside the “prostate’ [142]. The CIRS phantom is used as a training tool
for clinicians to get accustomed to ultrasound-based brachytherapy procedure.
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(a)

(b)

Figure 3.7: (a) CIRS Ultrasound Prostate Phantom (b) Side view [142].
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3.3.2 Rotatable Cylindrical Phantom
A rotatable cylindrical phantom as shown in Figure 3.8 was used for angular dependence
experiments in EBRT. It was designed and built by CMRP staff at UOW. This phantom
was constructed to allow a detector placed within to be rotated in a range of ±180 degrees.
The phantom is made from polymethyl methacrylate (PMMA) material of 1.17 g/cm3
density [143], and its weight is 35 kg. It's cylindrical in shape with a diameter of 30 cm
and 40 cm length [144], it has a central rectangular insertion slot of 20.5 x 15.5 x 5 cm3
to insert the detector that held in place by a rectangular PMMA board. The phantom’s
motion is controlled manually or automatically with an accuracy of ± 0.25 degrees. The
phantom was rotated in a clockwise direction as seen from the view direction shown in
Fig. 3.8.

Figure 3.8: The rotatable cylindrical phantom.
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3.4 Readout Systems
3.4.1 AFE Data Acquisition System (DAQ)
The analog front end (AFE) data acquisition (DAQ) system is used to read out the current
response from the skin diode detectors in this study. A commercial AFE0064 electrometer
produced by Texas Instruments (Texas Instruments, Dallas, United States of America)
was used in the analog frontend data acquisition system (AFE DAQ) [145, 146]. AFE006
was designed for readout of signal from the flat panels of x-ray imaging systems. It was
included as a key component of the data acquisition system by the Centre for Medical
Radiation Physics (CMRP) at UOW. The features of AFE0064 are 64 integrators, two
different output drivers, minimum scan time 28.32 μs and eight different sensitivity
ranges (from 0.13 pC to 9.6 pC). This flexible system design provides integration of either
positive or negative charges [147]. Table 3.1 and 3.2 summarize the specifications and
ranges.

Table 3.1: Texas Instruments AFE0064 Electrometer Specifications [147].

Number of channels

64

Min scan time

28.32 µs

Power dissipation

175 mW

Sequential mode frequency

15 MHz

Simultaneous mode frequency

3.75 MHz

Input current

30 µA

Operating temp. range

-40°C to 85°C

Integrator positive input voltage

1.68 V

Differential full-scale analog output

± 1.4 V
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Table 3.2: Analog Input Sensitivity Ranges for AFE0064 [147].

Range 0

0.13 pC

Range 1

0.25 pC

Range 2

0.5 pC

Range 3

1.2 pC

Range 4

2.4 pC

Range 5

4.8 pC

Range 6

7.2 pC

Range 7

9.6 pC

Figure 3.9 represents a schematic diagram of a single channel. The integrator output is
reverted to the reset-level by a reset switch, which is installed in each channel. In the
acquisition stage, the reset switch is opened, and the detector generates a current,
originated from the detector leakage current and incident radiation, which charges the
capacitor of the amplifier. This results in the production of an output voltage (V) from the
amplifier, which corresponds to the total amount of charge collected (Q) and the capacitor
size (C), (where Q = CV). At the end of the acquisition phase, the output voltage is
measured as the signal sample. The reset switch is then closed to begin the reset stage. A
rest reference sample is obtained by measuring the output voltage at the end of the reset
stage. After obtaining the ‘signal’ and ‘reset’ samples for every single channel, the
difference between them is analysed using a 16-bit quad channels analogue-to-digital
converter (ADC). The ADC output is shown as a percentage of the total scale for the
chosen range.
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Figure 3.9: AFE single channel diagram.

Figure 3.10: The AFE Readout chips.
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The resultant data from the ADC is transferred to a Field Programmable Gate Array
(FPGA) as in Figure 3.11, which transfers data between the AFE system and a computer
via a Universal Serial Bus (USB) link. The ‘dead time’ for measurement is almost 70 µs
for each measurement in the AFE DAQ system, but this is not wasted time, it enables the
transfer of data to the operator’s computer and the resetting (draining of stray charge) of
the DAQ capacitors.

Figure 3.11: The Field Programmable Gate Array (FPGA) board.

The AFE system starts measurements and integrates all input channels at the same time
after the commands and parameters are set by the system user. Figure 3.12 presents a
block diagram of the experimental setup showing the connection between the PC and the
detectors that were used.
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Figure 3.12: Diagram of the experimental setup.

The graphical user interface (GUI) Dual-Detector v1.1 developed by the CMRP was used
in this project as it has already been installed into a laptop computer. The detector reader
was connected to the laptop via a USB 2.0 connection. The GUI that has been compiled
using C++ language and controls the communication with the AFE readout system during
charge collection, as well as carrying out real-time data analysis. Response measurements
were obtained through this interface.

Figure 3.13: A screen shot of Dual-Detector v1.1 interface.
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As shown in Figure 3.13, the system user is able to change different measurement
parameters in this interface, such as: acquisition time, integration time, buffer size,
measurement frequency and sensitivity range. As the AFE DAQ system starts to operate,
Dual-Detector starts the connection to FPGA via a USB 2.0 connection. When the
response measurement begins in the interface, all the setting parameters are sent to the
AFE and response measurement is initiated. The frequency and the integration time are
set to reduce any noise associated with the measurements. The dose calculated dose
values from Dual-Detector software were compared with dose calculated by TPS which
was saved to the DICOM file.
The system maximum acquisition frequency is 10 kHz, while the minimum integration
time is 14 μs. In the data analysis window, the response of one skin diode detector in
terms of acquisition time at a dwell time of 77 s, frequency measurement of 360 Hz,
sensitivity range 4 and integration time of 1500 μs shown in Figure 3.14.

Figure 3.14: A screenshot of single-channel response.
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3.4.2 OneTouch readout system
The newly-developed OneTouch wireless read-out system shown in Figure 3.15, which
was developed by CMRP at UOW Australia, and used previously for MOSkinTM
measurements. The system includes temperature compensation and automatic calibration.
The reader design is capable of transmitting data from six individual detectors at one time.
The collected and digitised data transmitted wirelessly to a PC via USB receiver allowing
real-time dose measurements. The system bias voltage is ~ 9 V. The stable system and
the low bias voltage give an increase in the MOSkin detector's lifetime. Further
information about OneTouch wireless system please refers to Ref. [148].

Figure 3.15: OneTouch readout system for MOSkin detectors.

3.4.3 TERA readout system
In this study a multichannel charge-to-frequency converter TERA readout system was
also used to read out the current response from the skin diode detectors, as shown in
Figure 3.16. The TERA chip allows for large scale integration of charge and can serve 64
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channels simultaneously. The TERA system was designed by the Istituto Nazionale di
Fisica Nucleare (INFN) Torino Division, Italy, in a collaboration with the University of
Torino microelectronics group [149, 150] . The first design version of the TERA system
was used for ionising chambers in a pixelated ionisation detector called the Magic Cube
system for hadron therapy

[151, 152]. The TERA design is based on the conversion of

current to frequency and followed by a digital counter. It is applied with a chargebalancing integration technique [152]. An electric current is produced in the detector bulk
as a result of the interaction between incident radiation and detector material. The
generated current charges up the 600 fF integrator capacitor in the operational
transconductance amplifier (OTA) as shown in Figure 3.12. The result of the integrator
is a ramp voltage, which is compared with the threshold voltage by the comparator. If the
ramp voltage has a value that is higher than the value of the threshold voltage then the
comparator releases a calibrated pulse (VB) to the pulse generator (PG) which activates
the pulse generator to emit two pulses; the digital counter receives the first pulse, while
the subtraction circuit receives the second.
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Figure 3.16: Schematic diagram of TERA readout and the waveform at the nodes of the
converter [149].

The emitted pulse from the PG to the subtraction circuit will charge up the 200 fF
subtraction capacitor (Csub). The output responses of the Csub to Vsub is two delta-like
current pulses with an equal charge but opposite in polarity. Figure 3.17 represents the
timing between the charge subtraction and the gating signals. The amplitude of Vsub is
the difference between the two reference voltages (V pluse+ and V pluse-), which are set
externally between 0.5 and 3.3 V [151].

Figure 3.17: Charge subtraction waveforms [149].
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The two current pulse timing synchronise with the leading (δ+) and trailing (δ-) edge of
the voltage pulse. The current pulse with the same polarity as the voltage output of the
comparator is shorted to the OTA reference (Vref), and the other pulse is added
algebraically to the input current to subtract a charge quantum from the input current.
This leads to a sharp reduction of the charge across Cint (integration capacitor), in
proportion to the charge emitted by the subtraction circuit. At the end of the previous
process, if the input voltage to the comparator is higher than the threshold voltage, the PG
will continue to emit pulses to the counter and the subtraction circuit. As soon as the
integrated charge over Cint is lower than the threshold voltage, the comparator trigger is
reset, and PG stops emitting pulses.
CMRP developed the DAQ and software to collect and analyse data which enables both
offline and online data analysis. In this study, only three channels of one TERA chip
having 64 independent channels was used to read out three different skin diode responses.
Rad-X DoseViewTM software was used to produce a graphical presentation of the
detector's response in real-time.

3.5 Experimental Field Arrangements
In this thesis, experiments were performed in two modalities of radiotherapy; external
beam radiotherapy and high dose rate brachytherapy. All HDR BT experiments were
conducted in the brachytherapy unit in Cancer Care Centre (CCC) at St. George Hospital,
Kogarah. A Flexitron HDR remote afterloader (Necletron, Veenendaal, The Netherlands)
with 40 channels was utilised (in combination with Oncentrar Brachy Treatment Planning
System) for dose delivery as shown in Figure 3.18.
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Figure 3.18: Flexitron HDR “afterloader”.

In this study Ir-192 high dose rate Flexisource, (Veenendaal, The Netherlands) was used
at St. George Cancer Care Centre. Ir-192 was provided in the form of a thin steel-encased
pellet with diameter of 0.85 mm and a length of 4.6 mm. The actual source diameter is
0.6 mm with length of 3.5 mm. A cross section of the source pellet is illustrated in Figure
3.19.
The source strength is 40.7 mGy.m2.hr-1 (40700 U). The source strength degrades over
time, so the dwell time of the source adjusted for each treatment plan.

Figure 3.19: The design of the Flexisource Ir-192 HDR source showing all the dimensions
[153].
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The dose rate distribution for the HDR Ir-192 source (Flexisource) in a liquid water media
has been described by Granero et al. [153], by utilising the Monte Carlo code GEANT4.
The dose rate distribution studies were performed over a 2.5-140 mm distance range.
They expressed the dose rate per unit air-kerma strength in terms of y and z coordinates,
with z denoting the source's long axis and y is perpendicular to the long axis. In both the
y and z directions, the dose rate per unit air-kerma strength decreases rapidly as one moves
away from the source, resulting in a high dose gradient in close proximity to the source.
Figure 3.20 shows the dose per unit air-kerma strength for a line extending radially in the

Dose rate per unit air-kerma strenght
(cGyh-1U-1)
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Figure 3.20: Ir-192 dose rate per unit air-kerma strength for the line z = 0 [153].

EBRT experiments were performed with a Varian model 2100IX linear accelerator
(Varian Medical System, Palo Alto, CA) operating with a “flattened” photon beam at
energy 6 MV and a Varian Truebeam operating at 6 MV in FF and FFF modes, by
replacing the flattening filter with a very thin brass plate to generate the FFF beam and
Gulmay DX3300 orthovoltage x-ray therapy machine at the Illawarra Cancer Care Centre
(ICCC), Wollongong Hospital, as shown in Figures 3.21 & 3.22.
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Figure 3.21: The Varian Truebeam linear accelerator.

Figure 3.22: The Gulmay DX3300 orthovoltage x-ray therapy machine at ICCC.
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3.6 Conclusion
In this chapter, a description of the instruments used to complete this work has been
provided. First, the new n-type skin diode detector and MOSkin detector and second AFE
readout systems, oneTouch reader and TERA system were described. In addition, the
phantoms that were used in different experiments have been described. This chapter
covered details of the two dosimeters and how their readout system works, and the
software used. Moreover, the graphical user interface was designed for enabling a user to
communicate with the computer and change the parameters required for the experiments.
The characterisation of the skin diode detector to be used for dosimetry in HDR BT and
EBRT as a quality assurance tool, is presented in the following chapters.
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CHAPTER 4: Electrical Characterisation: I-V and C-V
4.1 Introduction
The analysis of the electrical characteristic of a semiconductor detector prior to its routine
use is necessary to ensure the suitability, efficiency and scaling factors of the detector.
Many factors can impact the performance of the silicon diode detectors such as the
structure, basic electrical characteristics and environmental influences. To determine the
quality of a p-n junction, it is important to measure depletion voltage, leakage current and
capacitance characteristics, as they may contribute significantly to noise generation in the
detectors, spatial resolution and efficiency of charge collection. Considering that the
diode works in reverse bias to be used as a radiation detector, the leakage current is of
great interest and it must be much less than the average current generated by radiation.
Leakage current refers to the imposed operating condition on a diode to determine the
bias voltage at which the ratio of signal to noise reach its optimum value. For ideal p-n
junctions the current density is given by the ideal diode equation [123] :

𝐽 = 𝐽𝑠 (𝑒

𝑞𝑉⁄
𝑘𝑇

− 1)

(4.1)

Where Js is the saturation current, q is the magnitude of electron charge, V is the applied
bias voltage across the diode, T is the temperature of measurement in Kelvin and k is
Boltzmann’s Constant. When a reverse bias voltage is applied, the current is saturated at
-Js which is given only by the summation of diffusion currents. In silicon junctions, the
typical diode equation provides a qualitative agreement because of the process of
generation and recombination of the charge carriers inside the depletion region. Under
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reverse bias in a silicon junction, the concentration of carriers falls lower than their
equilibrium concentrations. Accordingly, the current generated due to the generation of
the carriers inside the depletion region is given by the relation:

𝑥𝑑

𝐽𝑔𝑒𝑛 = ∫
0

𝑞𝑛𝑖
𝑞𝑛𝑖 𝑥𝑑
𝑑𝑥 =
𝜏𝑔
𝜏𝑔

(4.2)

Where xd is depletion region width, 𝜏𝑔 is the generation lifetime of charged carriers and
ni is the intrinsic carrier density. As long as the number of acceptors is much higher than
the number of donors and the reverse voltage, VR, is larger than 3 kT/q, the approximate
value of the reverse current density, jR, can be given by the sum of the diffusion current
in the neutral regions, jDiffusion, and the generated current, jgen, within the depletion regions
as shown in the following equation:

𝐽𝑅 = 𝐽𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 + 𝐽𝑔𝑒𝑛

𝐷𝑝 𝑛𝑖2
𝑞𝑛𝑖 𝑥𝑑
= 𝑞√
+
𝜏𝑝 𝑁𝑑
𝜏𝑔

(4.3)

The intrinsic carrier density for silicon is relatively small, thus; the reverse current density
equation is dominated by the current generation density. Therefore, the reverse current
density is nearly proportional to the depletion region depth of the p-n junction. The width
79

of the depletion region is increased as the reverse bias voltage is applied and is given by
the following equation:

𝑥𝑑= √

2𝜀0 𝜀𝑠𝑖 (𝑉𝑏𝑖 − 𝑉𝑅 )
𝑞𝑁𝑒𝑓𝑓

(4.4)

Where ε0 is the free space permittivity, εSi is the dielectric constant of silicon, Neff is the
effective impurity concentration of the detector, VR is the reverse bias voltage applied and
Vbi is the p-n junction’s built-in potential.
From equation 4.4 the square of the depletion region width is proportional to the applied
external bias voltage, and therefore, from equation 4.3 it can be said that the reverse
current density is also related to the applied external bias by the same proportion. The
impact of the device resistivity can be determined, since the resistivity, ρ, of the silicon is
given by the following equation:

𝜌=

1
𝜇𝑝 𝑁𝑒𝑓𝑓

(4.5)

Where μp is the mobility of holes and Neff is the effective impurity concentration of the
detector. Thus, from equation 4.4 it is clear that the depletion region’s width xd, and as a
result the reverse current density, is proportional to silicon bulk resistivity’s square root.
When silicon diodes in radiation detectors are operated in reverse bias mode, to get a very
low leakage current generated by the minority carriers (in contrast to the high current
produced in forward bias), this leakage current must be very small compared to the
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average current produced by incident radiation, as shown in Fig 4.1. Silicon diodes show
a junction breakdown when operated in a reverse bias at a greater bias voltage values than
the typical specified operating values for these diodes. Such a breakdown does not occur
in a forward biased mode of operation.
C-V characteristics can provide information about the electrostatic potential of a diode’s
depletion region thermal equilibrium, the width of its depletion layer and the effective
impurity concentration of the silicon detector. The capacitance of the depletion layer per
unit area is defined as:

𝐶𝑗 =

𝑑𝑄

(4.6)

𝑑𝑉

Where dQ is incremental change in depletion layer charge per unit area for an incremental
change in the applied voltage dV. The depletion capacitance per unit area is expressed
by:

𝑑𝑄
𝑑𝑄
𝜀𝑠
𝐶𝑗 =
=
=
𝑑𝑉 𝑊 𝑑𝑄
𝑊
𝜀𝑠

(4.7)

At thermal equilibrium, the width of the depletion layer can be written as:
2𝜀 𝑉𝑏𝑖

𝑊= √ 𝑠
𝑞𝑁
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𝑒𝑓𝑓

(4.8)

Where Ɛs is the semiconductor dielectric permittivity and q is the electron charge. When
reverse bias (-V) is applied across the p-n junction, the width of the p-n junction increases,
and this is shown by:

𝑊= √

2𝜀𝑠 (𝑉𝑏𝑖 −𝑉)

(4.9)

𝑞𝑁𝑒𝑓𝑓

From Equations 4.7 and 4.9, the capacitance of the depletion region is given by the
following equations:

𝐶𝑗 =

𝜀𝑠
𝑊

𝑞𝜀 𝑁

𝐵
= √2(𝑉𝑠 −𝑉
)
𝑏𝑖

(4.10)

or
1
𝐶𝑗2

=

2(𝑉𝑏𝑖 −𝑉)
𝑞𝜀𝑠 𝑁𝐵

(4.11)

Equation 4.11 shows that a plot of voltage versus the square of reciprocal capacitance
1/Cj2 produces a straight line. Where NB is the effective impurity concentration of the
detector. The slope of this straight line will reveal the concentration of impurity NB of the
substrate, with the y-intercept at the zero value for 1/Cj2 giving the built-in potential Vbi
[123].
The performance of the silicon-detector depends heavily on electrical properties including
depletion voltage, capacitance and leakage current. These properties have an impact on
noise formation, spatial resolution and charge-collection efficiency. Current-voltage (IV) and capacitance-voltage (C-V) characteristics of the epitaxial skin diode were obtained
in order to evaluate the uniformity of the detector response, to define baseline leakage
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current and to define the appropriate operating voltage for the detector at which the signal
to noise ratio is optimal.

Figure 4.1: I-V characteristics of a practical silicon diode, (a) generation-recombination current
region, (b) diffusion current region, (c) high-injection region, (d) series resistance effect, (e)
reverse leakage current due to generation-recombination and surface effect [126].

4.2 Current-Voltage (I-V) Characteristics
The I-V characteristics of several skin diodes were obtained using Keithley 230 highvoltage source to apply a bias voltage across the skin diode, coupled with the Keithley
614 electrometer for reverse current measurement. Figure 4.2 represents the setup for I-
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V measurements. All the parameters and data measurements were controlled by LabView
software.
LabView software allowed control of the parameters used in the measurements such as
the range of voltage, increment value, duration of delay time between the application of
bias voltage and the collection of the current over an increasing bias voltage range as
illustrated in Figure 4.3.

Figure 4.2: Schematic of the I-V test for skin diode.

Throughout the measurement process, the detector was kept inside a dark steel amber to
prevent any contribution of photocurrent generated from ambient light in addition to
preventing any electromagnetic interference. The measurements were carried out at room
temperature (~ 295 K) and at atmospheric pressure.
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Figure 4.3: The interface of the LabVIEWTM software

A reverse bias voltage from 0 V to 20 V with incremental steps of -0.5 V was applied to
the bulk (n+) substrate and the resultant current collected in the junction region (p+) was
measured. The delay time was 1000 ms (1 s) between the applied voltage and the collected
current.
All the uncertainties for I-V curves presented in this study are based on a 6.5-digit
accuracy scale of the instrument used. Changeable scales between 20 pA to 200 nA were
used, and the uncertainties range between 0.0002-2 pA.

4.3 Capacitance-Voltage (C-V) characteristics
C-V characteristic measurements were used to estimate the depletion bias of the detectors,
where the depletion bias is the voltage threshold, where any further increase in the bias
voltage will lead to no increase in the width of the depletion area and hence no increase
in the capacitance value. Furthermore, it is an important measurement to assess the
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influence of radiation on the effective doping concentration of the detector [154]. This
assessment can be made by measuring the capacitance versus the applied reverse bias.
The device capacitance is inversely proportional to the applied voltage, where any
increase in the applied voltage leads to a decrease in the capacitance up until full depletion
is reached. Any further increase in the applied voltage beyond the depletion voltage does
not change the width of the depletion area. The capacitance of the p-n junction can be
expressed by the equation:

𝐶=

𝑞 𝜀0 𝜀𝑠𝑖 𝑁𝑒𝑓𝑓
𝜀0 𝜀𝑠𝑖
=√
𝑥𝑑
2(𝑉𝑏𝑖 − 𝑉𝑅 )

(4.12)

where:
εsi = silicon dielectric constant
ε0 = the permittivity of free space
xd = the depletion region width
q = the charge of an electron
Vbi = the junction built-in potential
VR = the externally applied reverse voltage.
In this experiment, the C-V characteristics were measured by using a Boonton 7200
Bridge Capacitance Meter and C-V software; this device imposed a 1 MHz sinusoidal
wave onto the low diode detector input. Reverse bias voltages from 0 to -20, with
incremental steps of -0.5 V were applied to the diodes and 2000 ms (2 s) delay time was
86

arranged. The detector was placed inside a dark chamber at room temperature and before
each measurement the capacitance meter was set to zero value. The C-V software allows
the control of the parameters used in the measurements such as the range of voltage,
voltage increment value and duration of delay time. All data can be displayed, plotted and
stored by this software. It has an interface similar to the LabVIEW software as shown in
Figure 4.4.

Figure 4.4: The C-V software interface.

4.4 Results and discussion
4.4.1 I-V characteristics
The I-V characteristics of the skin diode detector were measured. Figure 4.3 shows the IV characteristics in reverse bias for several skin diodes. Each of the tested samples
demonstrates the expected trend. There is some variation between the detectors, which
occur due to the fabrication process.
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Figure 4.5: I-V Characteristics of n-type skin diodes detectors.

It is clear from Figure 4.5 that all n-type skin diode detectors follow the predicted trend,
namely that the reverse current increases with an increase in the applied voltage but at
different rates. Some detectors showed a quick increase in the reverse current such as
sample number 1, where the reverse current value was 0.00048 nA at zero voltage and
0.69 nA at voltage 20 V and sample number 6, where the reverse current value was
0.00092 nA at zero voltage and 0.65 nA at voltage 20 V. On the other hand, some samples
showed a lower increase in the current such as samples number 3 and 4, where the reverse
current value was 0.00023 nA and 0.00050 nA respectively at zero voltage and 0.07 nA
and 0.036 nA respectively at 20 V. In general, most detectors showed an increase in the
reverse current at a low breakdown voltage (approximately 20 V). In I-V characteristic
measurements the “uncertainties” come from the differences between the tested samples,
due to the inability of making exact device “clones” during the fabrication process, in
addition to the mount positioning variation of the detectors on their kapton pigtails,
surface defects, increasing leakage. Also, temperature has an impact during the
measurements whereby an increase in temperature leads to an increase in leakage current
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as a result of the increasing number of charge carriers. Errors can be reduced by increasing
the sample size of the detectors utilized in the measurements, ensuring a sufficient
connection to the kapton pigtail and measuring the variation in temperature during the
measurements.
In conclusion, the new skin diodes present a wide range of reverse currents. The expected
reverse current for small devices (1 x 1 and 0.5 x 0.5 mm2) at voltage 20 V should be
between 100-200 pA, but the observed range was 30-700 pA at 20 V for the skin diodes.
This may be related to the silicon growth and manufacturing processes.
4.4.2 C-V characteristics
The C-V characteristics of the skin diode detector were measured. Figure 4.6 shows the
C-V characteristics in reverse bias for several skin diodes. All skin diodes demonstrated
the expected C-V trend for silicon diodes detectors, which showed a maximum
capacitance with zero bias applied, and a gradual decrease in the capacitance as the
reverse bias increased.
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Figure 4.6: C-V characteristics of n-type skin diodes detectors.
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In Figure 4.6, the range of the applied reverse bias was from 0 to 20 V. As the negative
bias increased, all of the skin diodes’ capacitances at 20 V were found to be between 17.5
and 18.6 pF. However, a higher capacitance value was found for sample number 1 with
27.5 pF at zero reverse bias, while the lowest capacitance response was for sample number
6 with 25.5 pF at zero reverse bias. All of the capacitances are almost constant at large
negative bias voltages, corresponding to a high doping density. The capacitance of the
depletion layer is dependent on the applied reverse bias voltage and the dependence of
the capacitance on the impurity concentration of the substrate; therefore, the built-in
potential and the impurity concentration can be found by measuring the C-V
characteristics. 1/C2 is plotted as a function of the applied voltage as shown in Figure 4.7.
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Figure 4.7: 1/C2 vs reverse bias of n-type skin diodes.

The graph between 1/C2 and bias voltage does not give a simple straight line. The C-V
characteristics of the skin diodes follows the expected shape in two regions, as predicted
by equation 4.12, but there is another region interposed (between 7 and 10 V negative
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bias) where there is an increase in the capacitance due to the effects of oxide charge at the
SiO2 region on the capacitance.

4.5 Conclusion
The electrical characteristic of the new skin diode developed by CMRP were investigated
to indicate their suitability to be used as radiation detectors to measure skin doses in HDR
brachytherapy and external beam radiotherapy. I-V and C-V features were obtained to
determine the leakage current over depletion bias from 0 to -20 V. Six samples were used
and the results showed a variation between the detectors, which could be due to variation
in their manufacturing process. The capacitance of the skin diode samples obtained at 0
V applied bias were between 25.5-27.5 pF. While the capacitances obtained at -20 V
applied bias were between 17.57-18.66 pF. As a result, for the skin diode, the voltage
range between 5–10 V is suggested for the reverse biasing operation in order to prevent
diode breakdown.
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CHAPTER 5: Monte Carlo Detector Modelling

5.1 Introduction
Monte Carlo simulation code is now a valuable tool in the physics of radiotherapy and
radiation dosimetry. It is used to simulate photon and electron interactions with matter at
the levels of energy utilised in medical physics. GEANT4 for Geometry ANd Tracking,
is a software toolkit to simulate the passage of particles through matter, implemented by
C++ language. GEANT4 offers the basic simulation functions to describe the materials
and geometry of the detector, transport particles, describe the response of the detector,
track sequential movement of particles, provide an overall user interface and produce
visualizations of the results. Also, it offers a wide menu of physical processes to describe
particle-matter interactions over a wide range of energies. The wide application areas for
GEANT4 include high energy physics, space physics and medical physics.
Benchmarking of the GEANT4 simulation was carried out by comparing the depth dose
distribution obtained by the simulation to the dose distribution calculated by TG43 and
investigate the angular response of detectors.
The dose deposited in the sensitive volume of the detector is registered and presented as
the average dose deposited per primary particle simulated. Monte Carlo simulation were
performed with a silicon detector model irradiated by a single Iridium-192 HDR source.
The task of these GEANT4 simulations is to test the performance of the new skin diode
detectors using the computer software to model its characteristics and results such as
depth dose response and angular response.
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5.2 TG43 Calculations
The AAPM TG43 describes a dose calculation protocol for HDR brachytherapy. Dose
distribution around the radioactive source at different depths in the phantom were
calculated using TG43 formalism as presented in equation 2.2, Section 2.1.6, Chapter 2.

5.3 Liquid Water Model Simulation
The GEANT4 Monte Carlo code was utilised for further investigation on the Ir-192
spectrum changes with depth in a phantom. A liquid water model was used to compare
the simulation models against TG43 calculations and to investigate the energy
dependence of the detector in comparison to the liquid water model. The source used in
this study was the Flexisource (HDR) Ir-192. This source’s expected behaviour was
modelled using GEANT4 code. The active core of the source is a cylinder made of a pure
iridium (density 22.42 g/cm3) of a 3.5 mm length and 0.6 mm diameter. A type 304
stainless steel capsule of 0.85 mm radius and 4.6 mm length covers the active core which
has been welded to a steel cable. GEANT4 was used to obtain the dose distribution of the
Flexisource at various depths. The depth dose response was investigated from 8 mm to
35 mm from the Ir-192 radioactive source. The simulation was performed in a cubic water
phantom of dimensions 40 x 40 x 40 cm3. For each run, 500 million photons were
simulated to get good statistics. For each depth the simulations repeated 10 times. The
angular response was investigated in liquid water model as a “benchmark” for the
simulation. The simulation was performed for angle ranging from 0 to 360˚ in increments
of 30˚ around a model of the Ir-192 source to study the overall of angular response. Since
doses in water do not exhibit any angular dependence, this model was used to confirm
that there is no angular response effect.
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5.4 Silicon Detector Model Simulation
The silicon detector model simulation was performed to compare its results with the liquid
water model in order to study the effect of the skin diode geometry on the response. The
“Flexisource Ir-192 HDR source” and the “skin diode detector” were constructed in
GEANT4 to model the real source and skin diode detector. The geometric design of the
Flexisource is illustrated in Figure 5.1. The active pellet is 3.5 mm long, with a 0.6 mm
radius a contained within a stainless-steel-304 capsule of radius 0.85 mm and length 4.6
mm. The capsule attenuates the ß- particles to a negligible level. Attached to the capsule
at one end is a type 304 stainless-steel cable which is modelled as a cylinder of 0.5 mm
diameter. The composition of the modelled steel was 67.92% Fe, 19% Cr, 10% Ni, 2%
Mn, 1% Si and 0.08% C and a density of 8 g/cm3 [153]. In order to account for additional
scattering contributions from the steel cable as calculated in the treatment planning
system the steel cable was considered to be 10 cm length for the simulation. The detector
was constructed according to the information described in chapter 3 and illustrated in
Figure 5.1.
The simulation was performed in a cubic water phantom of size 40 x 40 x 40 cm3 and the
source was positioned in the centre of the phantom. The skin diode was positioned below
the source as shown in Figure 5.2. For each run, 500 x 106 photons were simulated in
order to acquire low statistical uncertainty. After a photon is “generated”, it passes
through the steel capsule before it reaches the phantom. Photons transport as per classical
geometry and are subjected to simulated interaction processes. Each simulation was
performed ten times, and the average dose was computed used for further analysis.
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Figure 5.1: Structural diagram of the Flexisource Ir-192 HDR [153].

Figure 5.2: Visualisation of the Ir-192 core and skin diode detector in GEANT4 simulation.

95

5.5 Results
5.5.1 TG43 Calculation
The results from the TG43 calculations for the depth dose response are presented in Table
5.1. All the results are normalised to the dose rate at 10 mm depth in the phantom. The
dose rate decreases with depth because of two factors: an attenuated exponential function
and the inverse square law due to spatial impacts.

Table 5.1 Depth dose response calculated by TG43 for an Ir-192 source in liquid water.

Dose rate (cG.hr-1)

Normalised dose rate

8

194.569

1.55

10

125.378

1.00

15

56.130

0.44

20

31.698

0.25

25

20.319

0.16

30

14.127

0.11

35

10.373

0.08

Depth (mm)

5.5.2. Liquide Water Model Simulations (Depth dose response)
Monte Carlo simulations in liquid model were carried out to “benchmark” the simulation
model against the accepted TG43 calculated values. The results of the depth dose
simulations are shown in Table 5.2. All the values were normalised to the dose rate at 10
mm source-detector distance. The percentage difference between the liquid water model
and TG43 were also presented. It can be shown that the results from Monte Carlo
simulation in liquid water and the TG43 calculation are in a good agreement as shown in
Figure 5.3. The average deviation was 0.93% ± 0.85 and all the simulation results lie
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within 3% of the TG43 values. At the depths lower than 30 mm the agreement was within
1.2% and for the depths greater than 30 mm was within 2.4%. The dose estimated by
Monte Carlo simulation was found to be in a good agreement with TG43 calculated values
~ 8%. As a result, it can be assumed that the Monte Carlo simulation applied to the Ir-192
source are accurately determine the relative dose in liquid water.

Table 5.2: Depth dose response of a skin diode according to the GEANT4 Monte Carlo
simulation in the liquid water model.

Depth (mm)

Total dose
(Gy/primary)

Normalised dose
rate

Percentage difference
with TG43

8

1.4417E-13

1.5575

-0.42

10

9.2561E-14

1

0

15

4.1497E-14

0.4483

-0.16

20

2.3581E-14

0.2547

-0.77

25

1.5164E-14

0.1638

-1.13

30

1.0671E-14

0.1152

-2.39

35

7.7848E-14

0.0841

-1.64
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Figure 5.3: A comparison of depth dose response using TG43 calculated values and Monte
Carlo simulation of a liquid water model. The statistical uncertainty of simulation was < 1%.

5.5.3 Silicon Detector Model Simulation
5.5.3.1 Depth dose response of the silicon detector
The results of the Monte Carlo simulations for the silicon detector model are presented in
Table 5.3, as well as the normalised response to dose at 10 mm depth and the percentage
differences in the liquid water model. The agreement between the liquid water and silicon
models was within ± 6% and the maximum difference is seen at the higher depths that
have the lowest dose rates. At depths less than 30 mm the agreement was within ± 2.5%.
Figure 5.4 represents a comparison of the Monte Carlo silicon models with TG43
calculated values. It can be seen that there is a good agreement between the results from
the GEANT4 simulations and the TG43 calculated values. All the results from the
simulations lie within ± 3% of the TG43 calculated values. The average deviation was (2
± 2)%. From the previous results it is clear that Monte Carlo simulations of an Ir-192
source are able to accurately predict the relative doses in silicon models to within ± 3%.
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Figure 5.4 shows a comparison of the depth dose response of the liquid water model with
a silicon model. It is clear that all results are in a good agreement.

Table 5.3: Depth dose response from Monte Carlo simulation of the silicon detector model.

Depth

Total dose

Normalised dose

Percentage difference with

(mm)

(Gy/primary

rate

liquid water model

photon)
8

4.19E-13

1.57

-0.75

10

2.67E-13

1.00

0.00

15

1.20E-13

0.45

-0.24

20

7.12E-14

0.27

-0.82

25

4.26E-14

0.16

2.61

30

3.06E-14

0.11

0.59

35

2.30E-14

0.09

0.14

2
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Figure 5.4: A comparison of depth dose response using TG43 calculated values and Monte
Carlo simulation of the silicon model. The statistical uncertainty of simulation was < 1%.
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Figure 5.5: A comparison of the depth dose response of the liquid water model with a silicon
model obtained from GEANT4 simulation. The statistical uncertainty of simulation was ~1%.

5.5.3.2 Angular response of the silicon detector
The angular dependence of the skin diode detector model was simulated by changing the
angle between the detector and a “Ir-192 source”. The detector was virtually placed at a
15 mm from the centre of the radioactive source. The response at angles ranging from 0˚
to 330˚ were compared to the value of the average response. The results of the GEANT4
simulation for angular response are presented in Table 5.4. All the results are within ±
4% of the average response. The heightened effect of the angular response can be seen at
angles 90˚, 180˚ and 270˚. This is due to the reduced number of photons deposited at a
90˚ or 270˚ angle of the detector and to the photon’s attenuation through the detector
substrate at 180˚ angle. The graph of the percentage difference from the average response
is shown in Figure 8.5.
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Table 5.4: The angular response from GEANT4 simulation of a silicon model at a depth of 15
mm.

Angle (˚)

Total dose (Gy/primary

Percentage difference

photon)

from average (%)

0

3.64E-14

2.2

30

3.49E-14

-2.2

60

3.51E-14

-1.6

90

3.69E-14

3.5

120

3.51E-14

-1.7

150

3.50E-14

-1.9

180

3.66E-14

2.4

210

3.52E-14

-1.4

240

3.56E-14

-0.15

270

3.62E-14

1.4

300

3.58E-14

0.37

330

3.53E-14

-1.1

Average

3.56E-14
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Figure 5.6: Percentage difference from the average response with angular rotations of a model
silicon detector. The error bars representing the uncertainties of the measurements of ten
repetitions.
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5.6 Conclusion
To prove the validity of the Monte Carlo simulation used in this study, the depth dose
response and angular response were studied for two detector models, the liquid water
model and a silicon detector model. The depth dose response was compared with TG43
calculated values. The liquid water model showed a good agreement (within 3%) with the
TG43 calculated values. The depth dose response values were within 1.2% for depths less
than 30 mm and within 3% for depths higher than 30 mm. Also, the silicon model showed
a good agreement within 3% with TG43calculated values.
The angular response of the two models were investigated at angles ranging from 30˚ to
330˚ in 30˚ increments. For the liquid water model, the results showed an isotropic
response. For the silicon model, the angular response was within 4% of the average
response.
The goal of the GEANT4 simulation was to develop a dosimetric system suitable for
brachytherapy. It was used to model the experimental setup in terms of materials and
geometry of radioactive sources and detectors used in brachytherapy. GEANT4 also
provided a convenient and user-friendly way to visualize the interactions of photons with
matter.
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CHAPTER 6: Characterization of the new Skin Diode
Dosimeter in high-Energy Photon Beam: Calibration,
Linearity, PDD and OF

6.1 Introduction
The skin dose measurement in external radiotherapy is important and its precise
measurement is a difficult task and not simple due to the high dose gradient at the entry
of the beam. The skin dose estimates of treatment planning systems (TPSs) is not always
accurate, therefore in-vivo measurements are very significant to realistically estimate the
skin dose delivered to the patient receiving radiotherapy and compare it with prescribed
dose. Quality assurance checking in radiotherapy is vital to minimise any errors occurs
during treatment planning and dose delivery and thus improve treatment outcomes. The
use of linear accelerator operating in “flattening filter free” mode (FFF) in radiotherapy
is increasing. Therefore, an understanding of the doses delivered with these beams is of
great interest and importance.
A photon beam aimed at a patient enters the patient’s skin surface and delivers a surface
dose. Under the skin’s outer surface, the dose rapidly increases from a lower value at the
surface until reaching a maximum value at a depth of dmax. Thereafter there is an
exponential decrease until the radiation exit point. The dose in the first 1 mm tissue can
rise by 30% [155].
The aim of this study is to evaluate the feasibility of utilising the new n-type skin diode
dosimeters with an epitaxial layer thickness of 7 μm as a quality assurance tool for in vivo
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skin dosimetry during external beam radiotherapy by studying its dosimetric
characteristics.
The following characteristics were investigated: dosimeter calibration, response linearity
and reproducibility, percentage depth dose (PDD) and output factor (OF). The parameters
were tested with 6 MV flattening filter and FFF photon beams. It is important to study
these dosimetric characteristics of the skin diode dosimeter in photon beams before
utilising it as an in-vivo dosimeter.
Vicoroski et al. in 2017 [156] studied the characteristics of two different diodes: p-type
silicon diodes with an epitaxial layer of 50 µm thickness and n-type silicon diodes with
an epitaxial layer of 5 µm thickness. They found that the n-type diodes differed from an
Attix ionisation chamber measurement by approximately 2%. As a further comparison,
the calculated dose from GEANT4 simulation differed by 0.5% from the diode readings
at a depth of 0.07 mm. Moreover, the study showed linearity of accumulated dose over a
range from 50 cGy to 500 cGy for both types of diodes (i.e. n-type and p-type) under the
standard conditions of 6 MV photon beam at dmax with a field size 10 x 10 cm2.

6.2 Methods
6.2.1. Calibration of n-type epitaxial Skin diode detector
A dose calibration factor was determined, for converting the response measured by the
skin diode to dose in cGy. The dose calibration factor was determined under reference
conditions in a solid water-equivalent phantomTM. The skin diode was placed at the dmax
depth and irradiated with field size 10 x 10 cm2 at SSD 100 cm, where 100 MU equals
100 cGy for the 6 MV photon beam at this location. A 10 x 10 cm2 field containing the
Skin diode detector was irradiated with 100 MU delivered and a dose rate of 600 MU/min.
The measurements were performed around the central axis of the photon beam on the
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surface of a 30 x 30 cm2 solid water-equivalent phantom and above 10 cm solid water
slabs of different thicknesses in order to have adequate backscatter conditions. The
average calibration factor was determined by the division of the charge response by 100
to convert skin diode response to dose in cGy. The absorbed dose was measured using
the following equation (6.1).

𝑨𝒃𝒔𝒐𝒓𝒃𝒆𝒅 𝑫𝒐𝒔𝒆 (𝒄𝑮𝒚) =

𝑪𝒉𝒂𝒓𝒈𝒆 𝑹𝒆𝒔𝒑𝒐𝒏𝒔𝒆 (𝒑𝑪)
𝑪𝒂𝒍𝒊𝒃𝒓𝒂𝒕𝒊𝒐𝒏 𝑭𝒂𝒄𝒕𝒐𝒓 (

𝒑𝑪
)
𝒄𝑮𝒚

(6.1)

6.2.2 Response linearity and Reproducibility
The linearity of the skin diode dosimeter was investigated in a 6 MV photon beam, under
the standard reference conditions of 100 cm SSD, with a field size of 10 x 10 cm2 and the
detectors placed at a depth of dmax in a solid water-equivalent phantom for FF and FFF
photon beams. With the LINAC set to deliver doses at a rate of 600 cGy/min and 1200
cGy/min respectively. The diode’s responses were measured for doses ranging from 5 to
500 cGy. All the measurements were taken three times for each MU irradiation and the
measurements' standard deviations were computed; then the averaged response was used
for further analysis. Detector reproducibility is influenced by the small random errors
associated with each measurement. Experimental uncertainties and measurement errors
were minimised by repeated measurements and final results from a set of measurements
were obtained by statistical methods. In this study, the reproducibility of the skin diode
detector was also assessed for both FF and FFF photon beams.
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6.2.3 Percentage Depth Dose
Percentage depth doses (PDD) measurements at SSD 100 cm for the skin diode detectors
were performed and compared to Wellhöfer CC13 ionisation chamber (active volume
0.13 cm3, active length 5.8 mm and diameter 6.0 mm). These measurements were
performed above a 10 cm solid water-equivalent phantom to provide adequate
backscattering conditions. The phantom size was 30 x 30 cm2. Solid Water slabs of
different thicknesses from 0.1 cm to 20 cm were used on top of the detector to obtain the
doses at various depths. The PDD were measured for 6 MV and 6 MV FFF photon beams
at a constant 100 cm SSD and 10 x 10 cm2 field size. The LINAC delivered 100 MU at
600 MU/min dose rate. The results are normalised to dmax and a comparison was made
with the measurements obtained by the CC13 ionisation chamber under the same
experimental conditions.
6.2.4 Output Factor (OF)
The ratio of the dose per monitor unit (MU) for a specific field size to the reference field
size in known as the output factor (OF) [157]. The reference field size, used in this study,
was 10 × 10 cm2, measured in the field’s centre at 10cm depth and source to surface
distance (SSD) of 90 cm, with 6 MV and 6 MV FFF photon beams. The measurements
were carried out by delivering 100 MUs each time for dose rates 600 MU/min and 1200
MU/min respectively. The readings were obtained in the field’s centre for each square
field jaw setting for field widths ranging from 0.5 x 0.5 cm2 to 30 x 30 cm2. The
measurements were repeated three times for each field size and the mean value was
utilised for experiment analysis. The mean measurement was normalized to 10 x 10 cm2
field size and compared with a CC13 ionization chamber (3 mm radius) from Wellhöfer
(Scanditronix) under the same conditions.
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6.3 Results and Discussions
6.3.1. Calibration of n-type Epitaxial Skin Diode Detector
The definition of silicon diode sensitivity is the charge collected per unit of absorbed dose
[158]. The skin diode was determined to have a mean dose calibration factor of 1278.17
± 30 pC / cGy The Skin diode sensitivity decreases as function of accumulated dose; this
happens due to the formation of radiation defects in the Silicon lattice, which causes a
reduction in the charge carrier lifetime. In a study conducted by Vicoroski et al., 5 µm ntype skin diode (Epi-5B) detector was irradiated with a Co-60 source to give 80 kGy total
accumulated dose in increments of 20 kGy. The response of the skin diode decreased as
a function of the accumulated dose. The response decreased for the first 20 kGy of the
cumulated dose by 25%. The response became more stable at an accumulated dose over
60 kGy with a small variation of 0.05% [156].
6.3.2 Response Linearity and Reproducibility
Figures 6.1 and 6.2 show the linearity response of the skin diode in a solid waterequivalent phantom for 6 MV and 6 MV FFF photon beams for accumulated doses
ranging between 5 cGy to 500 cGy. The y-axis represents skin diode dosimeter response
normalized to the response of the detector when irradiated with 50 cGy. The response of
skin diode was found to increase linearly with the delivered doses.
The response of the skin diode as a function of dose for both photon beam modes over
the range from 5 cGy to 500 cGy, showed linearity as seen in Figures 6.1 and 6.2. The
observed correlation coefficients R2 of the skin diodes were 0.9995 and 0.9999 for the 6
MV and 6 MV FFF photon beams, respectively. This is an expected feature for the utilised
diode detectors. The reproducibility of the skin diode detector response was calculated in
linearity test by calculating the mean standard deviation of three sets of measurements for
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each applied dose. The skin diode showed a good reproducibility with a deviation-line
behaviour of less than 1% between 5 cGy and 500 cGy.
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Figure 6.1: Dose response linearity of skin diode dosimeter for 6 MV photon beam and 10 x 10
cm2 field size with dose rate of 600 MU.min-1.
12

y = 0.0193x + 0.0366
R² = 0.9999

Normalised response

10

8

6

4

2

0
0

50

100

150

200

250

300

350

400

450

500

Accumulated Dose(cGy)

Figure 6.2: Dose response linearity of skin diode dosimeter for 6 MV FFF photon beam and 10
x 10 cm2 field size with dose rate of 1200 MU.min-1.
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6.3.3 Percentage Depth Dose
Figures 6.3 and 6.4 show the percentage depth dose of 10 x 10 cm2 fields obtained at 100
cm SSD using a skin diode dosimeter for 6 MV and 6 MV FFF photon beams. The results
were compared with a Wellhöfer CC13 ionisation chamber and a MOSkin detector under
the same conditions. The PDD was measured from surface to 20 cm depth in the solid
phantom. The measurements are normalized to the response at dmax. In Figure 6.3, it is
observed that the skin diode detector curve is in close agreement with both the ionisation
chamber curve and a MOSkin dosimeter. However, for the depth of first few millimetres
(up to 5 mm) the skin diode was under-responding and then over-responding consistently
up to the maximum dose depth, compared to the ion chamber. Moreover, beyond the
build-up region, the skin diode also over-responded with respect to the ion chamber. The
percentage differences between the skin diode readings and those for the dosimeters used
as reference (CC13) was presented as below:

% Difference =

𝐶𝐶13−𝑠𝑘𝑖𝑛 𝑑𝑖𝑜𝑑𝑒
𝐶𝐶13

𝑥 100

(6.2)

The percentage differences between the skin diode and the CC13 chamber were within ±
2%. The large deviation between skin diode and the MOSkin dosimeters occurring at the
surface of the phantom was 9.1%, which may be because of the different spatial resolution
of these detectors, but beyond the build-up region the percentage difference was less
significant, with the average percentage difference being 1.5%. The percentage difference
between the skin diode and MOSkin detector was within ± 3.6%. In Figure 6.4 the error
bars are difficult to notice because they are very small. The average percentage difference
between the skin diode and CC13 ion chamber for FFF photon beam, beyond build up
region was less than 1.7%. The result is in agreement with previous study of the (Epi5B) skin diode with a 5μm thick epitaxial layer. In this study the difference in PDD
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between the GEANT4 calculated values and the Epi-5B experimental values were within
± 2%. In the same study at 0.07 mm depth, a PDD difference of ~ 2% was found between
the skin diode and uncorrected Attix chamber [156].
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Figure 6.3: Percentage Depth Dose measured by a skin diode and compared with a CC13 ion
chamber and a MOSkin detector with a 6 MV photon beam of 10 x 10 cm2 field at 100 cm SSD.
The percentage differences are also shown between the skin diode and CC13 ion chamber, error
bars are small to be presented.
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Figure 6.4: Percentage Depth Dose measured by skin diode and compared with CC13 ion
chamber with a 6 MV FFF photon beam of 10 x 10 cm2 field at 100 cm SSD. The percentage
difference between the skin diode and CC13 ion chamber response is also shown, error bars are
small to be presented.

The percentage depth dose curve of a 6 MV “flattened” and “unflattened” photon beam
were measured on the central axis of a solid water phantom at SSD 100cm. Figure 6.5
shows the results obtained for field size 10 x 10 cm2. Although PDD values for FFF
beams tend to be higher than flattened photon beams at 5 mm depth and below, PDD
values for FFF beams at 5 cm depth and above were slightly lower than flattened photon
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beams, as shown in Figure 6.5. It is noticeable that the FFF mode has a steeper dose falloff with the depth in comparison to the flattened mode after reaching the maximum dose
at dmax. This steeper dose fall-off is due to the softening of the x-ray spectrum, where the
removal of the flattening filter means, the radiation “hardening” effect in the central axis
region of the beam no longer exist.
Hence, a slightly larger fraction of the energy from the FFF beam is deposited in the buildup region in comparison with deeper depths [159]. Figure 6.6. illustrates the build-up
region, which shows a slight rise in surface dose for FFF beam.
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Figure 6.5: PDD curves of 6 MV and 6 MV FFF photon beams at 100 cm
SDD of a 10 x 10 cm2 field.
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Figure 6.6: Build-up curve for 10 x 10 cm2 field in a solid water-equivalent phantom. FFF
beams show a slightly high surface dose, in comparison to flattened beams at 6 MV.

6.3.4 Output Factor (OF)
If a skin detector is irradiated with different field sizes, the detector will produce a higher
response at a larger field size. Figures 6.7 and 6.8 show the output factor measured by the
skin diode detector at a depth of 10 cm within a solid water-equivalent phantom and
compared to a CC13 ionization chamber for 6 MV and 6 MV FFF photon beams. Three
measurements were taken for each field size. The response is normalised to the measured
response at 10 x 10 cm2 field size. As expected, the detectors' response increases as the
field size increases. This relates to the increase in the number of primary x-ray photons
with larger field size and increase contribution of scattered photons [160] .
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Figure 6.7: Output Factor response at 10cm depth using a solid water-equivalent phantom
measured by Skin diode and CC13 ion chamber at various field sizes normalised to10 x 10 cm2
for a 6 MVphoton beam. The percentage difference between Skin diode and CC13 ion chamber
response is also shown.

The increased percentage difference between skin diode and CC13 ion chamber
measurements is caused by the difference in the water equivalent depth (WED) of the
skin diode in comparison to the ion chamber, which amounts to 70 µm. Nonetheless, the
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average percentage difference between the skin diode and CC13 ion chamber was within
1.8% for all the field sizes.
The skin diode showed a slight under response at the field sizes less than 10 x 10 cm2,
where the average percentage difference between the skin diode and CC13 was within
4.5%. For example, in a 3 x 3 cm2 field size, the OF measured with the ion chamber varies
from the skin diode OF measurement by approximately 6% and 3.3% for 6 MV and 6
MV FFF photon beams respectively. Furthermore, as the field size increases, the
percentage difference in the measurement uncertainty between the OF measured for the
skin diode and ion chamber detectors decreases. For larger field sizes (20 x 20 cm2), the
skin diode showed a slightly higher response than the CC13 ion chamber. For the larger
field sizes, the contribution of the lower energy scattered photons impacts the diode and
leads to an increase in the response of the skin diode compared to the ion chamber. It is
noteworthy that the output factor of the skin diode obtained a good proximity within 4%
of the ion chamber measurements for field sizes greater than 20 x 20 cm2. For the smaller
field sizes, a slightly larger variation of output factor was found, as indicated in Fig. 6.8.
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Figure 6.8: Output factor comparison between Skin diode and CC13 ion chamber. Data were
acquired at 10 cm depth using a solid water-equivalent phantom and normalised to 10 x 10 cm2
for a 6 MV FFF photon beam. The percentage differences are also shown.

The output factor measured by the skin diode dosimeter for 6 MV and 6 MV FFF photon
energies is shown in Figure 6.9 for square fields from 0.5 cm up to 30 cm in size. The
output factors ranged between 0.28 and 1.21 for 6 MV, 0.31 and 1.14 for 6 MV FFF. The
output factor of the “flattened” beam was higher relative to the FFF beam for field sizes
larger than 10 x 10 cm2, but smaller for field sizes smaller than 10 x 10 cm2. The ranges
of the output factors in 6 MV FFF are lower by 8% compared to 6 MV. The OF decreases
at large field sizes for the two photon beams is caused by reduction of head scatter, while
the phantom scatter is the same for both photon energies and depends on the field size at
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the phantom surface. In general, the head scatter variation for the FFF beam was
approximately 1.5% compared to 8% for the flattened beam for field sizes between 3 x 3
and 40 x 40 cm2 [161]. Therefore, FFF beams show reduced field size dependence. The
previous OF results were corresponding to the measurements performed at 10 cm depth.
Different reference dosimetric measurements were performed at 10 cm depth.
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Figure 6.9: Photon output factor (OF) response for square field sizes from 0.5 cm up to 30 cm
with “unflattened” and “flattened” photon beams.

The ion chamber is usually the best option for relative output factors measurements. But,
in the case of small fields, an ion chamber has a large size compared to the size of the
field diameter that is called volume-averaging effect. This leads to dose underestimation
as the whole chamber does not fit in to the central uniform beam intensity region [162].
In addition, the absence of lateral electronic equilibrium may occur anywhere in small
fields, even in field centre, which is near the detector edge [163]. Therefore, for small
field dosimetry, the detector size must be smaller than the field size radius.
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6.4 Conclusion
In-vivo dosimetry is a direct method to measure radiation doses during radiotherapy
treatments. It is a suitable method for identifying possible errors during treatment sessions
and to monitor treatment delivery in order to fulfil the treatment requirements. The new
n-type epitaxial “skin” diodes’ characteristics have been investigated in a solid waterequivalent phantom for linearity, percentage depth dose and output factor to determine
their suitability for in-vivo skin dosimetry.
According to the recommendations of the International Commission on Radiation Unit
and Measurements (ICRU) and The International Commission on Radiological Protection
(ICRP). The recommended depth for measuring or estimating skin dose is 0.07 mm. Due
to the very small sensitive volume of the skin diode detector, it is possible to use this
detector to measure skin dose. The results obtained in this study show a linear dose
response for the new skin diode in a range between 5 cGy to 500 cGy for 6MV FF and
FFF beams. The skin diode uncertainty for measuring the PDD was less than 1.7% beyond
the build-up region. For field sizes equal to or less than 3 x 3 cm2, skin diodes showed the
lowest output factor values, which may be related to the volume-averaging effect. The
new skin diode dosimeter has demonstrated that it can be used for skin radiotherapy
dosimetry. The new skin diode dosimeters gave good results in measurements of linearity
in dose response and in PDD measurements compared to a CC13 ion chamber.
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CHAPTER 7: Characterization of the New Skin Diode
Dosimeter: Energy Dependence, Dose Per Pulse, and Angular
Dependence

7.1 Introduction
Many factors should be taken into account when using a silicon diode as a dosimeter in
radiotherapy. For an ideal dosimeter, the energy response of the dosimeter should be
constant and independent of energy for a wide range of energies. In reality, this is not the
actual behaviour for most radiation dosimeters [164] . The energy dependence of silicon
diodes is attributed to the material surrounding the silicon die; which normally has an
atomic number higher than that for water, which leads to an energy dependence at photon
energies lower than 100 keV [165] . There is an increased ionization rate per unit volume
of silicon in comparison with water, which is related to the increase of photoelectric cross
section, σ, in higher atomic number materials (σ~ Z4 to Z5) [166]. The angular dependence
is important for in-vivo dosimetry [167]. In general, all commercial dosimeters display a
degree of angular dependence, due to their manufacturing process, dimensions and the
incident radiation energy [168]. Dose per pulse dependence (DPP) measurements refers
to assessing the change in detector sensitivity due to the change in the instantaneous dose
rate in a pulsed radiation beam of a medical LINAC. The aim of this chapter is to evaluate
the feasibility of using the new n-type skin diode dosimeter with an epitaxial layer
thickness of 7 μm for in-vivo skin dosimetry during external beam radiotherapy by
studying its characteristics. The following characteristics were investigated: energy
dependence in kilovoltage x-ray beam, dose per pulse and angular
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dependence in 6 MV and 6 MV FFF photon beams. Comparisons were performed with a
Farmer ionization chamber for DPP measurements. Consequently, an assessment of the
skin diode characteristics is therefore critical in order to check its suitability to be used as
a quality assurance tool for a medical linear accelerator.

7.2 Methods
7.2.1 Energy Dependence
In this study, an evaluation of the energy response of a new n-type epitaxial skin diode
for low energy photon beam dosimetry was performed. Most dosimeters exhibit
overestimation of the dose at low photon energies when operating in water. This is due to
the fact that photoelectric absorption is the predominant interaction of photons at
relatively low photon energies. The dose sensitivity of a silicon detector increases with
decreasing incident photon energy. The relevant experiment was carried out using x-ray
beams with kilovoltage potential from [164, 169]. 50 to 250 kVp from the Gulmay
DX3300 orthovoltage x-ray therapy machine at ICCC. The system was calibrated to
deliver a maximum dose at the phantom surface.
A 10 cm diameter cone at 30 cm face-to-surface distance (FSD) was used for energies
ranging from 50 kV to 150 kV and a 10 cm diameter cone at 50 cm FSD was used for the
energies 200 & 250 kV. Table 7.1 details the filter specific characteristics of the x-ray
beam qualities used in this study. The skin diode was placed on the surface of a 30 x 30
x 10 cm3 solid water phantom. The low-energy photon beam was delivered to the front
face of the skin diode as show in Figure 7.1. The measurements were repeated three times
and the average reading was calculated for experiment analysis.
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Table 7.1: Illustrates the characteristics of the filters used to deliver the x-ray beam qualities
including: Filter number, kilovoltage peak (kVp), tube current (mAs), and Half value layer
(HVL).

Filter No.

kVp

mAs

HVL

1

50

30

1.4 mm Al

2

75

29

2.5 mm Al

3

100

28

3.0 mm Al

4

125

23

5.0 mm Al

5

150

14

6.0 mm Al

6

200

13

0.5 mm Cu

7

250

12

1 mm Cu

Figure 7.1: Energy dependence measurement setup.
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7.2.2 Dose per Pulse
Dose per pulse (DPP) measurements where obtained to assess the variation in the
sensitivity of the detector due to a change in instantaneous dose rate in a pulsed radiation
beam delivered by the linear accelerator. The DPP decreases with increased SSD. All
diode detectors show some change in sensitivity with SSD; thus, it is important to evaluate
the new skin diodes’ behaviour before routine use can be approved for medical linac
measurements [170, 171] . According to a study conducted by Rikner and Grusell [172]
and other studies, the sensitivity of the n-type silicon diode to changes in dose per pulse
is higher than that for p-type silicon diodes. Hence an increase in sensitivity with
increased dose per pulse is expected [173, 174]. This is due to the decreased number of
unoccupied recombination-generation (RG) centres in n-type diodes compared to p-type
diodes, which allows for higher charge collection and consequently increases the device
sensitivity with dose rate.
The dose per pulse measurements were performed by measuring the skin diodes’
responses when placed at dmax in a solid water-equivalent phantom of 30 x 30 cm2 with
10 cm solid water-equivalent slabs for full backscattering and irradiation with a 10 x 10
cm2 field size of 6 MV and 6 MV FFF photon beams. The dose rate for the 6 MV and 6
MV FFF beams was 600 MU/min and 1200 MU/min respectively. The SSD changed from
80 cm to 350 cm. The frequency of pulsing for 6 MV and 6 MV FFF photon beams was
360 Hz. The gantry was set at 90°, and the upper face of the detector was perpendicular
to the horizontal radiation beam as shown in Figure 7.2. A Farmer 0.6 cm3 thimble
ionisation chamber (NE2571) was used under the same conditions as a reference. The
PTW UNIDOS electrometer with a supply voltage of -300 volts was used to measure the
charges from the Farmer ionisation chamber.
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The skin diode sensitivity (pC/Gy) is the ratio of the diode response in charge (pC) per
unit of absorbed dose (Gy) measured by the Farmer ion chamber at the same SSD. The
dose per pulse response of the detector was found by normalising the sensitivity ratio of
the detector at any SSD to the sensitivity ratio at SSD 100 cm.

Figure 7.2: Dose per pulse measurement setup using, a Varian trueBEAMTM x-ray LINAC.

7.2.3 Angular Dependence
The epitaxial skin diode as a planar silicon detector, has intrinsic angular dependence. To
estimate accurately the skin dose from different incident beam angles, the intrinsic
angular dependence should be investigated. The reference condition of irradiation is when
the angle between the linac head (gantry) and the detector surface (face up) is zero
degrees. When the angle between the linac head and the detector increases, the detector
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response decreases. The reduction in the detector response is due to the reduced charge
collection efficiency. Therefore, it is of concern to investigate the angular response when
the incident beam is oblique to the detector (not perpendicular). There are many factors
affecting the charge collection efficiency and the angle of irradiation such as the structure,
geometry, the material surrounding the sensitive area (packaging of the detector) and type
of the detector. The angular dependent relative response of the skin diode was defined as
the ratio between the diode response at any beam incidence angle and the response at a
zero-incidence angle.
In this study, the angular response of the new skin diode was investigated by placing the
skin diode in the centre of a cylindrical PMMA phantom of diameter 30 cm and rotating
the linac gantry from 0˚ to 180˚ in increments of 15˚. Irradiation of the skin diode at each
angle were performed using a field size of 10 x 10 cm2, for 6 MV and 6 MV FFF photon
beams irradiated by a Varian trueBEAM linac at the ICCC as shown in Figure 7.3. The
detector was positioned at the isocentre of the accelerator. Three measurements were
taken for each angle and the average reading was used. The average response at each
angle was normalised to the detector response at an incidence beam angle of 0˚.
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Figure 7.3: The skin diode on a PMMA rotatable cylindrical phantom in the angular dependence
measurement setup.

7.3 Results and Discussions
7.3.1 Energy Dependence
The energy dependence of the kVp x-ray beam with a skin diode is shown in Figure 7.4.
The results of the skin diodes were normalised to their response in 6 MV photon beam at
dmax, where the maximum dose for a kilovoltage beam is on the surface. Typically, most
diodes used for in-vivo dosimetry exhibit energy-dependence under x-ray photon beams.
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Figure 7.4: Skin diode energy dependence. The response is normalised to the dose obtained
from a 6 MV photon beam, the error bars are small to be presented.

The results have been normalised to the response of the skin diode at 6 MV photon beam
energy. The skin diode dosimeter exhibited a non-linear response at x-ray energies below
250 kVp. The graph showed dose enhancement 1.34 times higher for the skin diode at 50
kVp compared with the dose when exposed to a 6 MV photon beam. As mentioned in
Section 7.1, this is due to the increase of photoelectric cross section at low photon
energies.
Figure 7.5 shows the results of the skin diode normalised to their response at 250 kV
beam energy. The graph shows that the maximum difference in diode response was ~7
times greater than its response at 250 kV. Heightened detector responses can be seen at
energies lower than 200 kV; for example, the response at 150 kV is ~4 times greater than
that at 250 kV, while for 200 kV the response is ~1.3 times greater than 250 kV. The error
bars are too small to be shown in the graph.
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Figure 7.5: Skin diode energy dependence. The responses are normalised to 250 kV beam
energy. (250 kV is the maximum energy allowed for use with the orthovoltage machine), the
error bars are small to be presented.

7.3.2 Dose per pulse
Figures 7.6 and 7.7 show the DPP dependence of the new skin diode at dmax in a solid
water-equivalent phantom at 100 cm SSD with a field size of 10 x 10 cm2 for 6 MV and
6 MV FFF photon beams. The responses were normalised to 2.8 x 10-4 Gy/pulse and 6.48
x 10-4 Gy/pulse respectively, which represents the response of the ion chamber at dmax
depth with field size 10 x 10 cm2 in 6 MV and 6 MV FFF photon beams. The error bars
representing the uncertainties of the measurements are one standard deviation of the three
repeated measurements.
The increase in the skin diode response with increased dose rate (Gy/pulse) is due to the
recombination and generation process for electrons and holes in the semiconductors that
occurs via the material’s trapping mechanisms [75]. The 6 MV results shows that the
maximum DPP dependence for the all dose rates was within approximately 5%. At
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distances below 150 cm (clinical distance for treatment) the decrease of the skin diode
sensitivity is within 2%. The results show a good agreement with the study conducted by
Saini et al. for different commercial n-type and p-type silicon diodes used in in-vivo
dosimetry [158]. The skin diode response results show clearly and measurably the DPP
dependence in 6 MV FFF beams. A maximum DPP dependence of 10% at 0.994
mGy/pulse was noted.
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Figure 7.6: DPP response of a “skin diode” detector in a 6 MV photon beam. This response is
normalised to the DPP of a 28 x 10-4 Gy/pulse at a depth of dmax and SSD of 100 cm.
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Figure 7.7: DPP response of “skin diode” detector for 6 MV FFF photon beam. This response is
normalised to the DPP of a 6.48 x 10-4 at a depth of dmax and SSD of 100 cm

7.3.3 Angular Dependence
Figures 7.8 and 7.9 shows the intrinsic angular dependence results of a skin diode as a
function of the incident beam angle from 0° to 180°. The relative angular response was
normalised to the detector response at a standard angle of zero degrees (perpendicular
beam) for 6 MV and 6 MV FFF photon beams. The angular dependence of the skin diodes
decreased with decreasing incident angle of the beam because of their intrinsic
arrangement and material. This leads to a variation in attenuation and to the scattering of
photons and electrons that reached the sensitive volume of the detector when irradiated
from different angles. As shown in Figure 7.8, the angular dependence for photon beams
with “flattening filter” is greater than that for flattening filter-free beams. At 60° angle the
response measured for flattening filter beams is 0.14% greater than flattening filter-free
beams. The average intensity difference between the two photon beams was within 2%.
The relative detector responses, normalised to the response at 0° beam incidence, was
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found to decrease down to a minimum of 80% and 81% for 6 MV and 6 MV FFF photon
beams respectively. For both photons beams the minimum were reached at incident angle
180° due to the higher attenuation of the incident beam in the diode substrate in this
orientation.
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Figure 7.8: Normalised intrinsic angular response of skin diode at the centre of the cylindrical
phantom of 6 MV photon beam, error bars representing the uncertainties of the measurements

130

1.1

Relative Response (AƟ/A0)

1

0.9

0.8

0.7

0.6
0

15

30

45

60

75

90

105

120

135

150

165

180

195

Angle (degree)

Figure 7.9: Normalised intrinsic angular response of skin diode at the centre of cylindrical
phantom for 6 MV FFF photon beam.
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Figure 7.10: A comparison between the normalised intrinsic angular dependence of a skin diode
in 6 MV and in 6 MV FFF photon beams. The measurements were done at the centre of the
cylindrical phantom of diameter 30 cm. The reference incident angle is zero degree.
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7.4 Discussion
This study presented preliminary results from testing of a new n-type epitaxial skin diode
dosimeter developed at CMRP to perform a reliable real-time in-vivo dose verification.
In this phantom study, the skin diode response in low energy beam, skin diode sensitivity
with dose per pulse and skin diode response with different irradiation angles were
investigated to evaluate the feasibility of this dosimeter for clinical utilisation.
Dependence on the dose rate is also a key parameter for solid-state radiation detectors and
their dose per pulse variance have been examined. The sensitivity of skin diode varied by
5.5% and 11% over this range of dose per pulse for 6 MV and 6 MV FFF photon beams
respectively. Because the skin diode dosimeter dose not have cylindrical shape, the diode
sensitivity response possesses degree of angular dependence. The angular response of the
skin diode was measured to accurately assess the impact of tangential beams on skin dose
deposition.
Finally, it may be concluded from the results of this study that n-type epitaxial siliconbased detectors with “drop-in” packaging can be used for radiotherapy dosimetric
verification.
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CHAPTER 8: Characterization of the New Skin Diode
Dosimeter for use in High Dose Rate Brachytherapy

8.1 Introduction
Brachytherapy is a method of cancer treatment in which small radioactive sources are
used to deliver radiation inside or near the target to be treated. High dose can be delivered
locally to the target, while rapid dose falloff in the surrounding healthy tissues occurs,
which leads to improved localisation of the dose delivery to the target. The dosimetric
characteristics of skin diodes were measured to assess their suitability to be used as
dosimeters in HDR brachytherapy quality assurance. Results suggest that skin diode
detectors can be used to measure the dose to an anterior rectal wall or to the breast within
± 5% based on the fact that a significant percentage of dose points usually occur in clinical
practice outside of a 3% tolerance [175].
Precise dose measurements are vitally important in HDR brachytherapy at regions in
close proximity to the source and, because of the large dose gradient associated with HDR
source, any small deviation in the measuring position results in a significant variation in
the measured dose.
This study assesses the percentage depth dose of skin diodes at various distances from an
Ir-192 source, the angular dependence of the skin diode detectors and the effect of
backscatter conditions. Measurements were performed at St. George Cancer Care Centre,
Kogarah, using the Flexitron HDR remote afterloader.

133

8.2 Methods
8.2.1 Detector calibration
To convert the response of the skin diode from the readout system into an absolute dose
value, a dose conversion factor was required. The calibration factor (CF) was calculated
for skin diodes with a 10 Ci Ir-192 high dose rate source in a solid water-equivalent
phantom. This phantom consists of solid water-equivalent slabs of different thicknesses
as shown in Figure 8.1. The distances between the detectors and the source were changed
by inserting extra slabs between them. Adequate solid slabs were also used above the
source and below the detector to provide a full backscatter condition. The HDR
afterloader machine transports the radioactive source into the source cable then to the
plastic catheter, which was inserted inside one of the solid water-equivalent slabs. The
skin diode detectors were calibrated by irradiating the phantom with an Ir-192 source
delivered by Flexitron system. The responses were measured three times and the average
reading computed and compared to the TG43 formula calculated dose to calculate the CF.
In this chapter many skin diode detectors were used, and before every experiment the
detectors were individually calibrated. The calibration factor for each skin diode was
calculated by dividing the average charge collected by the calculated TG43 dose, as
shown in the following relation:

CF =

𝐶ℎ𝑎𝑟𝑔𝑒𝑠 (𝑝𝐶)

(8.1)

𝐷𝑜𝑠𝑒 (𝑐𝐺𝑦)
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Figure 8.1: Solid water-equivalent phantom used for CF measurement.

8.2.2 Depth Dose Response
The distribution of the dose around the HDR brachytherapy source is complex and affects
dose characterisation. Skin diode dosimeters were used to measure the dose in a solid
water-equivalent phantom at different distances from the Ir-192 radioactive source as
shown in Fig. 8.1, to investigate their dosimetric accuracy. The depth dose response of
the skin diode detector was compared to the dose calculated by the TG43 brachytherapy
dose calculation formalism. Three measurements were taken for each depth.
Percentage depth dose (PDD) values were measured in a solid water-equivalent phantom.
The Ir-192 source was arranged to dwell directly perpendicular to the face of the skin
diode. The skin diode was set to measure the response before, during and after the source
dwelling in order to subtract the baseline readings. Integration time was changed from
100 µs to 2000 µs to reduce any skin diode response fluctuations.
The source to detector distance was increased from 5 mm to 35 mm between the skin
diode and Ir-192 source to quantify their dosimetric accuracy when irradiated by a
radioactive source. The response readings were measured three times, and the average of
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the measurements was taken for analysis. The depth dose response of each skin diode
detector was compared to the dose calculated by the TG43 formula. Any small deviations
in position from the correct intended depth leads to a large variation in the dose rate.
Therefore, accuracy in positioning is important to achieve accurate measurement of the
dose.

8.2.3 Angular Response
During HDR brachytherapy treatment a dosimeter may be exposed to radiation from a
wide range of distances and angles. The sensitive detection volume of the skin diode is
assembled within a thin Kapton polyamide pigtail by a “drop-in” technique. With the
small volume of detection, the angle of radiation incidence is likely to have a
commensurable impact on the detector’s response. In comparison, most silicon diodes
also exhibit angular dependency [176, 177]. The directional response of the diodes is due
to geometrical factors associated with the construction of the detector. In the literature,
there several attempts have been made to quantify the angular dependence of various
kinds of diodes [105, 177, 178]. For epitaxial diode detectors, several factors contribute
to the observed asymmetric behaviour, such as incorrect alignment of the detector
sensitive area from the central axis and non-symmetric diode design due to the thickness
of the substrate and the Aluminium contacts. For accurate measurements the dosimeter
response would ideally not depend on the angle of radiation incidence. The angular
response of the skin diode was characterised at various angles in the radial and azimuthal
direction.
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8.2.3.1 Radial Angular Response
The radial angular response of skin diodes was measured at different angles around their
central axis as indicated in Figure 8.2. The solid water-equivalent phantom utilised to
conduct the radial angular measurements is indicated in Figure 8.3. In order to keep a
constant distance between the source and the dosimeter with varying irradiation angle,
the detector was placed in the centre of a split-cylindrical guide piece of water-equivalent
material of diameter 21 mm. The cylindrical piece consists of two halves, with a thin
groove made along the central axis to house the skin diode and its cable. The cylindrical
piece is in turn inserted into a hole through the side of solid water slab of 30 mm thick as
shown in Figure 8.4. The skin diode inside the cylindrical piece is aligned with the Ir192 source at 16 mm SDD and the angle of irradiation is changed as desired. The dose
response was obtained by sending the Ir-192 source to a single dwell position and rotating
the cylindrical piece in a clockwise direction around the central axis of the phantom at
angles ranging from 0° to 360° in 30° increments.

Figure 8.2: Diagram of radial angular response measurement around the central axis of skin
diodes.
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Figure 8.3: Angular phantom with cylindrical detector guide piece.

Figure 8.4: Radial angular response measurement setup.

8.2.3.2 Polar Angular Response
The polar angular response was also measured at various angles. The measurements were
made by irradiating the skin diode with Ir-192 source at different dwell positions in a
single catheter parallel to the detector as shown in Figure 8.5. The Ir-192 source was
progressively moved inside the catheter and remained at different dwell positions while
successive measurements were taken. As shown in Figure 8.5, there are different
incidence angles and different source distances for each dwelling position of the source
catheter. The source catheter channel is positioned 15 mm above the sensitive volume of
the skin diode and, the source was stepped into the catheter in 5 mm steps in the axial
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direction to adjust the polar angle between the source and diode detector. The diode
response was measured at corresponding points centred around the 0 mm source position.
The measurements were performed three times and the average readings were used for
analysis.

Figure 8.5: Diagram of polar angular response measurement.

8.2.4 Flip Sensitivity Variation
The new epitaxial skin diode detector was assembled with a drop-in technique on a kapton
pigtail. The sensitive volume is located at 7 mm water-equivalent depth on the top face
of the detector with a 6.5 µm epitaxial layer and 0.380 mm thick silicon substrate. Due to
the small water-equivalent depth for the incident radiation at the top face of the detector
compared to that at the underneath face, the “flip sensitivity” (i.e. the sensitivity when
radiation enters the back of “flip” side of the device) was investigated to study the effect
of changing the orientation of the detector.
The experiment was performed by comparing the absorbed dose on the top face to the
absorbed dose on the underneath face of the skin diode and MOSkin detectors. The
measurements were tested with backscatter material and with an air cavity, to estimate
the differences in response. The skin diode was placed in a solid water-equivalent
phantom for the “no air cavity” experiment and a cuboid cavity of 2 cm length and 1 cm
width was used for the cavity measurements. The skin diode detector was placed at a
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distance of 1.5 cm from the Ir-192 source. The experiments were repeated for face-up
and face-down “flip” detector orientations. The measurements were repeated three times
and the average of 3 results was computed and used for comparisons.

8.2.5 Comparison of Backscatter for Air Cavity and No Air Cavity with different
angles between the source and the detector
This purpose of this experiment was to investigate the absorbed dose which could be
expected to the anterior rectal wall in two conditions: air cavity and no air cavity, at
different angles and distances between the source and detector. Doses were measured at
different offset distances between the source and the detector with decreasing angles as
illustrated in Figure 8.6. The experiments were performed using solid water-equivalent
slabs of various thicknesses to create a “no air cavity” phantom and a cuboid cavity was
created with length of 2 cm and width of 1 cm for the “air cavity” phantom. For the cavity
measurements the detector was taped to the anterior wall of the cuboid cavity. The
distance between the skin diode and the Ir-192 source was set to 15 mm (above the centre
of the detector). For both sets of measurements, the source stepped away in both directions
from the central position, in increments of 5 mm. Three measurements were taken, and
the average values computed and used for comparisons. The results for both backscatter
conditions were also compared.
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Figure 8.6: Set-up of the backscatter experiment showing the air cavity.

8.3 Results
8.3.1 Detector Calibration
The dose calibration factor was found for each skin diode and MOSkin detector, irradiated
with an Ir-192 HDR source. The detectors were calibrated by irradiating them for 10
seconds at a distance of 15 mm from the HDR source. The calibration factor was
calculated by dividing the average response by the TG43 calculated dose at that depth.
For calibration of both detectors, the measurements were repeated three time and the
average value was used for analysis. The detectors were calibrated at the beginning of
each experiment.
8.3.2 Depth Dose Response
Figure 8.7 shows the depth dose curve obtained with the skin diodes and comparison with
the TG43 calculated values. The dose readings taken by the skin diode detector were in
good agreement with the TG43 calculated value. The difference between the measured
and calculated doses was likely to increase with the distance from the source. The dose
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measured with skin diode at a depth of 35 mm were only 1.5 cGy less than the dose
calculated by TG43, i.e. 7.6% less than the calculated dose. The discrepancies at large
distances are due to the low dose (19.16 cGy) delivered to the skin diode dosimeter at this
depth. Also, this may be related to the incomplete scatter environment in the solid waterequivalent phantom. Different studies report on the effect of the phantom size in
brachytherapy dosimetry studies. In a study conducted by Melhus et al. [179] , to provide
a full scatter condition for an Ir-192 radioactive source, a spherical phantom with diameter
of 80 cm to 100 cm is needed, whereas the smaller phantom leads to a lower dose
delivered to the points at increasing distances from the source. A dose discrepancy can be
seen between the measured and calculated dose at 5 mm depth, where the skin diode
response is 5.7% lower than the calculated dose. This uncertainty at a close distance to
the source is due to setup uncertainties that affected the dosimeter positioning accuracy.
According to a study by Lambert et al. [180] on the effect of setup error, it was found
that the placement error is more significant at close distances to the source and decreases
with increasing distance. According to the TG43 formalism, 1 mm deviation in distance
from the source will lead to a decrease in the dose rate of 30% at a depth of 5mm, due to
the steep dose gradient.

142

1000
TG43
Skin diode

Dose (cGy)

100

10

1
0

5

10

15

20

25

30

35

Depth (mm)

Figure 8.7: Dose measurements taken with a skin diode dosimeter in a solid phantom at various
distances from the Ir-192 source compared to the TG43 calculated dose, error bars representing
the uncertainty in skin diode response.

8.3.3 Angular Dependence
The dosimeter response varies with the direction and incidence angle of the radiation
beam based on its structure, size and, shape, as well as the characteristics of the incident
beam. In this study, the variation in the skin diode response vs. incidence angle was
investigated. Figures 8.8 to 8.10 showed both radial and azimuthal angular dependence
measured for different skin diode detectors
8.3.3.1 Radial Angular Response
The diode angular dependence is defined as the ratio of the diode response at any angle
(RƟ) over the diode response at angle zero (R0), as defined by the relation:

A=

𝑅(Ɵ)

(8.2)

𝑅(0)
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The angular response dependency of the skin diodes for a full 360˚ rotation was examined.
The radial angular dependence of the epitaxial diode response is shown in Figure 8.8,
with the response normalised to 100% at 0˚ angle. The radial angular data were obtained
using the cylindrical guide piece inserted in the phantom as shown in Figure 8.3. The
uncertainty regarding angle determination was ± 2.5˚ for this phantom. The response
uncertainty was within 1.85%, which is attributed mainly to the electronic noise with use
of a detector mounted on a kapton tail. The skin diode showed noticeable angular
dependence as a large reduction in the response of the diode was measured at the angles
150˚ and 210˚. The large variation in response is shown at angle 210˚. Around 180˚ the
fluctuation was 4.6% (for the angles range between 120˚ and 270˚). Overall, the largest
deviation in percentage relative to 0˚ angle was 19 ± 2% at 210˚. The data shows a
variation in diode response of 16.3% between the top face (at 0˚) and the bottom face (at
180˚) of ta typical epitaxial skin diode detectors, however it showed an acceptable ± 5%
of variation for angles range within 0 ± 60˚ and 180 ± 60 ˚. Given this, the skin diodes
displayed low fluctuations within ± 30˚ to the top face (0˚) and bottom face (180˚)
positions.
Due to the fabrication of the diodes, it is expected that this type of detector shows a degree
of angular response dependence. In accordance with previous studies, the diode showed
an under-response as the incidence angle of the beam increases [176, 177] .
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Figure 8.8: Radial angular response of a skin diode over a 360˚ range using an Ir-192 source.
(Results were normalised to 0˚), error bars represent the uncertainty in response ± 1.8%.

Our results demonstrated conformity with previous reports, whereby the diode responses
were not significantly reduced until the angle was more than 60˚ away from the top
surface of the device. The detected angular dependence results from a number of effects
associated with the detector which includes different photon path length across the 380
μm n+ substrate layer, anisotropies existing in the silicon chip and asymmetry in the
Aluminium contacts. Due to these effects, a variable photon attenuation occurs according
to their path. There is an increase in the response seen for the positive angles due to the
increase in the scatter radiation from the skin diode pigtail. The slightly asymmetrical
radial angular response of the detector around 180˚ may be due to the positioning error of
the sensitive volume below the Ir-192 source. In a radial angular response experimental
setup, any small lateral deviation of the sensitive volume from the central axis would have
a considerable effect on the diode’s angular response which is attributed to the depth
change with changing angle. Because of high dose gradients in HDR brachytherapy, any
small error in the placement of the detector can lead to a significant change in the response
of the detector.
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For comparison, the radial angular dependence of the MOSkin response is shown in
Figure 8.9 with the response normalised to the mean response. The results show the
response of the MOSkin was within ± 5% of the mean response for nearly thirteen
measurements taken from 0 to 360˚.

Response (%)

1.1

1

0.9

0.8
0

30

60

90

120

150

180

210

240

270

300

330

Angle (°)

Figure 8.9: Radial angular response of a MOSkin detector over a 360˚ range using an Ir-192
source. (Results are normalised to the mean response).

8.3.3.2 Polar Angular Response
The polar angular response was measured using the solid water-equivalent phantom and
an Ir-192 source. The position of the Ir-192 source was varied in increments of 10 mm
ahead of and behind the detector position. Each dwell position of the source produced a
different incidence radiation angle for the skin diode and different distance between the
source and the detector. The polar angular response measurements were compared to the
calculated dose using the TG43 formula at different angles and distances as shown in
Figure 8.10. The percentage differences R were calculated using the formula from
equation 8.3:
Percentage difference (R%) = ((A – B) / A) x 100
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(8.3)

Where, A = doses calculated by TG43, and B = measured point doses by skin diode
detector.
Three measurements for each angle were taken and the average was calculated and used
for further analysis. It can be seen that the response was in a good agreement with dose
calculated by the TG43 formula at all angles. In general, the response was within ± 4% of
the calculated dose at the different dwell positions utilised for this experiment. As in the
previous section, there is an increase in the response seen for the positive angles due to
the increase in the scatter radiation from the skin diodes’ pigtails.
For HDR brachytherapy dosimetry, the dose at the region of interest is the sum of the
delivered doses from all dwell positions at all dwell times inside the catheter, therefore,
it is of great importance to accurately measure the dose at different angle and distances
from the source.
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Figure 8.10: Percentage difference of skin diode and TG43 at various polar angles and
distances.
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8.3.4 Flip Sensitivity Variation
The flip sensitivity variation test was performed for the skin diode and MOSkin detectors.
The results are shown in Figures 8.11 and 8.12. It is clear that the maximum sensitivity
of the detectors occurs in the face-up orientation, and the percentage difference between
the absorbed dose for the detectors without air cavity and with air cavity was 4.2% and
4.4% for skin diode and MOSkin detectors respectively. While the lower sensitivity of
the detectors occurs in the face-down orientation (where the radiation enters what would
usually be thought of as the back or base of the device), and the percentage difference
between the absorbed dose for the detectors without air cavity and with air cavity was
11.6% and 3.9% for skin diodes and MOSkin detectors respectively. For both face-up and
face-down orientations of the detectors, the no cavity doses were higher than the air cavity
doses, which is expected because of the increased backscatter produced by the solid
water-equivalent material the phantom. Therefore, the comparison ratio, expressed in
percentage, was:

𝐶𝑜𝑚𝑝𝑎𝑟𝑖𝑠𝑜𝑛 𝑟𝑎𝑡𝑖𝑜 =

𝑑𝑜𝑠𝑒 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑏𝑎𝑐𝑘𝑠𝑐𝑎𝑡𝑡𝑒𝑟
𝑑𝑜𝑠𝑒 𝑤𝑖𝑡ℎ 𝑏𝑎𝑐𝑘𝑠𝑐𝑎𝑡𝑡𝑒𝑟

(8.4)

The “depth” between the source and the detectors was 15 mm. With faceup orientation,
the skin diode dose with no backscatter material was 53.7 ± 0.4 cGy while the dose with
backscatter was 56.1 ± 0.6 cGy. Therefore, the comparison ratio was 95.7%. With
facedown orientation, the skin diode dose with no backscatter material was 39.3 ± 0.5
cGy while the dose with backscatter was 44.5 ± 0.2 cGy. Therefore, the comparison ratio
was 88.35%. With faceup orientation the MOSkin detector dose with no backscatter
material was 50.7 ± 0.3 cGy while the dose with backscatter was 52.9 ± 0.2 cGy.
Therefore, the comparison ratio was 95.6%. With facedown orientation the MOSkin
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detector dose with no backscatter material was 40.4 ± 0.3 cGy while the dose with
backscatter was 42.1 ± 0.2 cGy. Therefore, the comparison ratio was 96 %.
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Figure 8.11: Comparison of the absorbed dose for face-up and face-down orientations of a skin
diode with air cavity and no air cavity and percentage difference.
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Figure 8.12: Comparison of the absorbed dose for face-up and face-down orientations of a
MOSkin detector with air cavity and no air cavity and percentage difference.

8.3.5 Comparison of Backscatter for Air Cavity and No Air Cavity with different
angles between the source and the detector
Figure 8.13 shows the measurements of absorbed dose with air cavity and no air cavity
conditions at a depth of 15 mm. The offset distances were set to be away from the position
of the maximum dose both ahead of and behind the detector in 5mm increments. As
shown in Figure 8.13, the maximum dose rate is at the 0 mm offset position where the Ir192 source is directly above the centre of the detector’s sensitive volume. For all offset
distances, the no cavity doses were higher than the cavity doses, which is expected due to
the presence of the backscatter material which increases the amount of the backscatter. It
can be seen that, as the offset distances increased, the variation between the cavity and no
cavity conditions decreased. At zero offset distance, the measured cavity dose was found
to be 10.7% less than the dose with no cavity. With increased offset distance the
150

difference dropped to 3.7% as shown in Figures 8.13 and 8.14. The decrease in the
difference is related to the reduction in the backscatter due to the increased attenuation
and scatter of primary photons. In addition, the Ir-192 is a line source, which means fewer
photon are emitted from the source’s two ends relative to the long length of the source.
Therefore, at the angles smaller than 90 ˚, fewer photons were emitted to the detector.
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Figure 8.13: Comparison of the absorbed dose in two conditions; air cavity and no air cavity, for
different source-detector offset distances at depth of 15 mm.
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Figure 8.14: The percentage difference in dose rate between air cavity and no air cavity doses at
15 mm depth.

8.4 Conclusion
The dosimetric characteristics of the new skin diode dosimeters were investigated. These
characteristics include, depth dose response, angular dependence, flip sensitivity, and
backscatter material effect. By comparison with the treatment planning system, the skin
diode dosimeter was able to measure with reasonable accuracy the dose response at
different depths. The angular dependence of the skin diode dosimeter was investigated
for Ir-192 gamma rays, in both polar and azimuthal directions, ant it was observed that
the skin diode responses are within 5% and 4% for polar and azimuthal directions
respectively. The ability of the skin diode to precisely measure the dose with variations
in both distance and angle is of vital importance if the skin diode is to be used for clinical
HDR brachytherapy dosimetry because the dose delivered to a certain point along the
rectal wall is the sum of all delivered doses at each dwell position in the source catheter.
The skin diode detectors’ sensitive volume is situated at 70 µm water-equivalent depth
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from its front face with a 380 µm thick silicon substrate behind the sensitive volume.
Considering the very small WED for radiation incident to the front face relative to that of
the back, the flip sensitivity was investigated to quantify how this will affect the
sensitivity of the detector. It was found that the difference in response between the front
face and back face was within ± 5% for the face-up orientation and within ± 12% for the
face-down orientation for skin diodes and MOSkin detectors. When there was no air
cavity, measurements of the absorbed dose were noticeably higher than in cavity
measurements of the absorbed dose, due to additional backscattering material.
Our experiments show that skin diode dosimeters have good performance in HDR
brachytherapy which confirm that they are appropriate for in-vivo dosimetry as a clinical
dosimetry device. The ease of use and online readout capability makes skin diodes an
attractive potential tool for in-vivo dosimetry, although further work is required to
improve the skin diodes’ stability by reducing their small unwanted response to ambient
non-ionising radiation i.e. providing stray light protection.
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CHAPTER 9: In-Vivo Dosimetry for Clinical Use

9.1 Verification of an HDR Brachytherapy Treatment Planning
System
Following the characterisation of the skin diode for the gamma spectrum of an Ir-192
brachytherapy source, a skin diode dosimeter was utilised to verify the treatment planning
system for skin dose during prostate and breast HDR BT.

9.1.1 Comparison of TPS calculated dose with skin diode detectors placed on
TRUS probe in HDR Prostate BT Treatment
The incidence and extent of complications arising from a specific type of treatment for
prostate cancer has become an important subject of concern, as the current modalities of
radiotherapy used to treat prostate cancer are all capable of providing successful tumour
control. The rectal complications are varying degrees of serious consequences in different
prostate treatment modalities such as external beam radiotherapy, intensity-modulated
radiotherapy, low dose-rate brachytherapy, and high dose-rate brachytherapy. The
advantages of BT treatment include ease of administration and lower morbidity compared
to radical prostatectomy or external beam radiotherapy (EBRT), and the recorded benefits
of prostate brachytherapy relative to radical prostatectomy and EBRT include lower
levels of incontinence and sexual dysfunction [181, 182].
Prostate brachytherapy, however, may lead to proctitis from radiation since the rectum is
adjacent to the prostate and is in a fixed location, meaning that the rectum is repeatedly
exposed to a significant dose of radiation in prostate brachytherapy. While there have
been several reports of urinary morbidity after brachytherapy, which to some extent
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affects almost all patients, the reports on rectal morbidity are fairly sparse [183, 184].
Rectal complications have been reported in a number of studies, in which the risk of
proctitis following radiation brachytherapy is stated to be between 1% and 9%, and rectal
bleeding is reported by between 2% and 10% of patients [183, 185].
In HDR brachytherapy treatment with a large fraction sizes, inevitably accompanied by
high dose-rate delivery to the rectum, which is in close proximity, there is a lot of concern
about rectal well-being and the need for quality assurance tests during prostate
brachytherapy is thus increased. Any proposed rectal dosimeter for HDR brachytherapy
treatment quality assurance should be capable of measuring the total dose delivered to the
rectum during the treatment session and then comparing this with the dose estimated by
the TPS. If the measured dose does not agree with the calculated dose within a certain
limit, as specified by the clinician, treatment should be stopped to avoid the risk of rectal
toxicity. The next goal of the study was to test if the skin diode detectors mounted on the
TRUS probe were appropriate for real-time rectal dose measurements during HDR BT
for prostate treatment.
9.1.1.1 Methodology
At St. George Hospital a Real-Time Ultrasound Planning, Oncentra Prostate (OCP) v4.2.2
(Elekta AB, Stockholm, Sweden), is used in HDR prostate brachytherapy treatment as
shown in Figure 9.1. The HDR system used at St. George Hospital includes a Flexitron
HDR remote “afterloader”. This experiment demonstrates that the arrangement of skin
diode detectors integrated with the TRUS-probe may provide an appropriate method for
taking real-time absorbed dose measurements on the anterior wall of the rectum during
prostate treatment.
For this experiment a Computerised Imaging Reference System (CIRS) Ultrasound
Prostate Phantom was utilised, which made it possible to optimise the treatment plan
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utilising ultrasound images with a phantom implantation procedure. Skin diode detectors
were integrated with a transrectal ultrasound (US) probe to perform (as a single
instrument) the dual-purpose of treatment imaging and real time anterior rectal wall
measuring for in-vivo dosimetry. The skin diodes were mounted on the TRUS probe.
During the experiment, the US probe was placed inside the “rectum” region of the
phantom to simulate the real positioning within the patient’s body during clinical
treatment.

Figure 9.1: Real time ultrasound planning system with CIRS Ultrasound Prostate Phantom for
quality assurance at St. George Hospital, Kogarah, prior to phantom implantation.

A CIRUS Ultrasound Prostate Phantom and Oncentra Prostate treatment planning system
(OCP TPS) were used to perform this experiment. The skin diode detectors were
integrated with the TRUS-probe, transforming it into a Dual-Purpose Probe. A DualPurpose Probe was also used in a study conducted by Tenconi et al. [186] and Carrara et
al. [187], in which Three MOSkin detectors were integrated with the TRUS- probe using
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a treatment planning system. The dose to the anterior rectal wall was measured, the total
dose at the detector positions was calculated and was used as points of comparison to the
recorded doses by the skin diode dosimeters. The ultrasound phantom was implanted by
a medical physicist at St. George Hospital under ultrasound guidance and the treatment
plan was optimised after each implantation. An endocavity balloon was utilised to mimic
the real clinical set-up for prostate treatments. The purpose of using the endocavity
balloon is to remove any air gaps around the rectal probe that might affect ultrasound
resolution. After the implantation procedure, the rectal probe was removed to attach the
skin diode detectors, and was placed back in the prostate phantom, the same process as
utilised in clinical cases.
9.1.1.2 Calibration of skin diode dosimeters
The calibration of the skin diode detectors was performed using a solid water-equavalent
phantom, the detectors were placed at a 15 ± 0.5 mm SDD. Three skin diode detectors
were used in this test and each detector was irradiated with 400 cGy. For accuracy, the
dose calibration test was repeated three times and the average value was used for analysis.
9.1.1.3 Skin diode integrated to the TRUS probe and TPS comparison
After the calibration processes a treatment plan was completed using the Real-Time
Ultrasound Planning System, with 9 Gy as a prescribed dose. The target contour consists
of the whole prostate gland and a 5 mm margin. The contoured organ at risk (OARs) were
the urethra and rectum. The prostate volume had a 100% dose coverage, with V150 being
23.5%and V200 being 5.3%, (V150 is the target volume that receives 150% of the
prescribed dose, while V200 receives 200%). It is recommended that 2 cc of the rectal
volume receive less than 70% of the prescribed dose. Eighteen catheters were inserted
into the CIRS Phantom using a standard arrangement utilised at St. George Hospital.
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Three skin diode detectors were placed onto the ultrasound probe (Type 8848, BK
Medical Systems, Herlev, Denmark) and sealed with Kapton tape, the first detector placed
at a distance 10.0 ± 0.5 mm inferior to plane of the transverse transducer of the ultrasound
probe with a gap of 15.0 ± 0.5 mm between the centre of each detector as shown in Figure
9.2. The skin diode dosimeters were positioned on the surface of the probe at an angle of
90˚ from the transducer, in order not to cause any perturbation in the production of the
sagittal and transverse images. According to the standard brachytherapy treatment
protocol, an endorectal balloon was used to cover the TRUS probe to increase the quality
of the collected images and to simulate the clinical set up during prostate brachytherapy.
A condom was then placed over the balloon prior to the start of the treatment in order to
provide extra protection against the possibility of infection or breakage of the balloon.
The TRUS probe was re-inserted into the CIRS phantom and the treatment plan was
readjusted. The skin diode detectors were then irradiated five times in accordance with
treatment plan.
The treatment plan can be seen in Figure 9.3, with percentages of the planned dose shown
over the ultrasound image of the prostate phantom. Figure 9.4 demonstrates the
experimental set-up for the detector’ comparison tests.
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Figure 9.2: Positions of the skin diode detectors on the transrectal ultrasound probe.

Figure 9.3: Real-time ultrasound treatment plan, Oncentra Prostate (OCP).
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Figure 9.4: Experimental set-up of CIRS phantom implanted with dual purpose probe and HDR
BT catheters, ready for treatment delivery.

9.1.1.4 Results
Three skin diode dosimeters were used for a dose response comparison with the TP. The
dose was measured at the three positions along the probe using the calibrated skin diode
detectors. Determination of the CF was done in a solid water-equivalent slabs, with 4 Gy
delivery dose and 15 mm source to detector distance. The average Calibration Factor of
the skin diodes utilised in this study was 1735 pC/cGy 1824 pC/cGy and 1372 pC/cGy
for the three detectors respectively. Five clinical treatment irradiations were completed
with the skin diode detectors and TERA readout system. The dose was determined at the
three points along the TRUS probe. The average values were used for analysis as shown
in Table 9.1. The percentage dose proportional to the total prescribed dose was
determined utilizing the treatment plan in addition to the distance-to-agreement for each
measured point as shown in Table 9.2.
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Table 9.1: Dose readout from skin diode detectors over 5 clinical treatment irradiations and TPS
doses.
Location

Test 1

Test 2

Test 3

Test 4

Test 5

Average

TPS

(mm)

(cGy)

(cGy)

(cGy)

(cGy)

(cGy)

Dose (cGy)

Dose (cGy)

10

267.9

266.6

265

262.3

268.7

266.1±2.5

276.4

25

362.8

362.6

357.6

357.7

358.4

359.8±2.6

373.5

40

378.6

377.6

376.1

377.3

376.7

377.5±1.1

406.7

Detector
1
Detector
2
Detector
3

Table 9.2: Comparison of skin diode detectors with the relative dose of the Ultrasound Planning
Oncentra Prostate and distance-to-agreement.

Detector

1

2

3

Average Dose (Gy)

2.66±2.53

3.59±2.61

3.76±1.12

Relative Dose Percentage (%)

29.56±1.30

39.98±0.29

41.94±0.14

OCP TPS Relative Dose

30.78

41.51

45.19

1.2

0.7

1.4

Percentage (%)
DTA (mm)

The skin diode detectors’ response was assessed in terms of their agreement with the
treatment plan’s relative doses, illustrated in Figure 9.5. Childress and Rosen identified
the normalised agreement value, which was the deviation for the percent dose difference
[188]. The average normalised agreement based on the OCP TP dose of the skin diode
detectors (relative dose % divided by OCP TPS relative dose %) was 0.95 ± 0.01.
The measured values for detectors 1 and 2 are less than TPS values by 4.6% and 3.6%
respectively. While the results for detector 3 was found to deviate below the treatment
plan dose by 7.1% as can be seen in Fig 9.6.
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Figure 9.5: The agreement of skin diode detectors with Oncentra Prostate Treatment
Planning System.
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Figure 9.6: Percentage difference of absorbed dose between TP doses and measured doses,
using three skin diode dosimeters on the TRUS-probe.
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9.1.1.5 Discussion
There is currently no routine in-vivo system for high-dose rate brachytherapy, resulting
in unknown potential errors and complications during treatment owing to the increase
dose delivery in a very small region.
The dosimetric ability of several skin diode detectors (active detectors) that could be used
as in-vivo dosimeters for clinical brachytherapy was investigated in this experiment.
Three skin diode detectors were calibrated before the clinical test in a solid waterequivalent phantom for three times and the average was used for analysis. The skin diode
dosimeters were positioned on the TRUS probe, in order to produce a dual-purpose probe.
The OCP treatment planning system was applied. The skin diode detector doses were
measured and recorded and compared with the dose calculated by the TPS at the same
positions. The detectors’ in-vivo dosimetric abilities were compared to the TPS predicted
dose and DTA. The skin diode detectors along the rectal probe recorded average doses of
266.1 ± 2.5 cGy at position 10 ± 0.5 mm, 359.8 ± 2.6 cGy at position 25 ± 0.5 mm and
377 ± 1.1 cGy at position 40 ± 0.5 mm. Table 9.2 shows the predicted dose percentage
from the OCP system and the calculated dose percentage of the skin diode detectors. The
DTA was calculated, too. The average DTA for the skin diode detectors was 1.1 ± 0.4
mm which lies within acceptable limits (< 3 mm). The normalised agreement for the skin
diode dosimeters was 0.95 ± 0.01. The skin diode detectors demonstrate potential in-vivo
dosimetry abilities compared to the existing clinical dosimeters, with an acceptable
agreement with the doses of the treatment plan and low DTA values. Rather than
depending on the dose distribution calculated using TRUS-based TPS, a dosimetry device
enabling real-time measurements of the rectal dose would be useful in deciding if the
rectal dose is consistent with the dose calculated using TPS.
163

9.1.2 HDR breast brachytherapy treatment with Skin Diode Dosimeters
The goal of this part of the study was to examine the dosimetric accuracy of the new skin
diode dosimeters for measuring skin dose during high dose-rate breast brachytherapy and
compare it with TPS, EBT3 films, and MOSkin dosimeters. The effective depth of
MOSkins is 70 µm [189], and the effective depth of EBT3 film is 0.153 mm [136, 190].
A gel breast phantom was utilised, and doses were measured with skin diodes at 6 points
in order to compare the skin diode measurements with the treatment planning system,
MOSkin detectors and EBT3 films.
9.1.2.1 Methodology
In order to reasonably simulate the physical properties of a real breast, a breast phantom
was constructed as a simple phantom made for measurement using gelatine formulation.
It is suitable for catheter localisation as shown in Figure 9.7(a). This phantom can be
reused if it is refrigerated between uses. A computed tomography (CT) scan was used to
set the catheters and detectors positions to verify a match between a real patient breast
treatment plan and the breast phantom. Subsequently, CT scans with a slice thickness 2
mm were conducted on the breast phantom. In order to identify the positions of skin diode
detectors in CT image reconstruction, small radiopaque spots were put above the surface
of the phantom at the detector’s positions. An Oncentra Brachy 4.5 system was used for
treatment planning, with several isodose curves planned as shown in Figure 9.8.
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(a)

(b)
Figure 9.7: (a) Gelatine-breast phantom; (b) breast phantom with 9 implanted catheters and
detector positions. Radio-opaque surface markers show up as faint blue beneath the tapes
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Figure 9.8: Oncentra brachy planning for breast phantom

The total treatment dose was 40.8 Gy. It was planned to deliver this dose in 12 fractions,
with 3.4 Gy in each fraction. In order to perform this brachytherapy treatment, 9 empty
catheters were implanted into the breast phantom as shown in Figure 9.7(b). All the
detectors were calibrated before starting the treatment plan. After calibration and CT
scaning, all catheters were connected to the afterloader machine and detectors were
connected to the readout systems (TERA & OneTouch). The treatment plan was repeated
for skin diodes, MOSkins, and EBT3 films with different detectors positions i.e. three
positions for each delivery to obtain three measurements.
9.1.2.2 Calibration of the detectors
The calibration of skin diode and MOSkin dosimeters was performed using a solid waterequivalent phantom at a distance of 10 mm using an Ir-192 radioactive source
((Flexisource, Elekta Brachytherapy, Veenendaal, The Netherlands). Three irradiations
were performed for each detector and the average value was utilised for analysis.
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Gafchromic EBT3 film was also used in this study. For calibration, the film sheet was cut
into strips of size 2.5 x 4 cm, 10 pieces were used for the calibration and 12 pieces were
used for clinical measurements. Before exposure, each film was scanned using an
EPSON 10000XL Photo Flatbed Scanner. Each film was scanned six times to warm up
the scanner for better film analysis accuracy, and the last three film scans were retained
for analysis. EBT3 films were positioned at the centre of the scanner with the same
orientation in order to minimise any systemic errors. Each film was scanned using 48-bit
RGB colour mode at a resolution of 72 dpi [191].
To obtain a film dose calibration curve, EBT3 films were irradiated using an Ir-192
brachytherapy source, at a depth of 1.5 cm in a solid water-equivalent phantom with
adequate backscatter material. The calibration film doses were (0 Gy, 1 Gy, 2 Gy, 3 Gy,
and 4 Gy). For full development, all films were kept for at least 48 hrs. In order to prevent
any potential darkening of the film, all the films were kept in unexposed UV area. The
“Image J” software package was used to identify the pre-scanning intensity (Io) and the
post-scanning intensity (I). The optical density for each film was calculated using the
following formula described by Device et al. [192, 193].
𝐼𝑜

𝑂𝐷 = 𝑙𝑜𝑔 ( 𝐼 )

(9.1)

The EBT3 films were scanned before and after irradiation in order to read and record the
net optical densities, and the optic density-dose calibration curve was obtained [191, 194].
Davic et al. and Battum et al. recommend that a second or higher-order polynomial should
be used to fit the non-linear calibration curve [195, 196]. Figure 9.9 shows the calibration
curve used in this study.
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Figure 9.9: EBT3 film calibration curve

9.1.2.3 Results
The average calibration factor for the skin diode detectors used in this study was 112.6 ±
5.7 pC/cGy. While the average calibration factor for MOSkin detectors was 2.27 ± 0.01
mV/cGy. The EBT3 film dose-response curve was obtained by combining the net optical
density derived from three EBT3 film samples for the selected doses between 0 and 4 Gy.
In this study, the surface radiation dose of the breast phantom was measured using skin
diodes, MOSkins, and EBT3 film detectors to quantify whether the measured doses are
consistent with the TPS doses for the gel breast phantom. The breast phantom was
designed to resemble true breast tissue by using a gel material widely used as a bolus in
radiotherapy. Before use, each detector was calibrated to verify its accuracy for real-time
measurement. The breast treatment was performed using nine catheters, at six points in
the breast volume. The dose was read, and the average value was used to assess the
reliability of the skin diode dosimeter to be utilised as an in-vivo dosimetry tool.
The response of the skin diode, MOSkin and EBT3 film detectors, is shown in Table 9.3.
The results demonstrate a good agreement between the values of the dose obtained by
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skin diode dosimeter and the values of the dose obtained from the TPS. The measured
mean skin diode doses were lower than calculated by TPS. The dose calculation relies on
the depth and the angle of incidence between the source and the radiation detector.
Depending on position, the doses at the measured points ranged from -1% to -15% below
the TPS dose, with standard deviations ranging from 0.5% to 4%. Furthermore, the air
tissue interface causes a higher dose loss, which indicates that when the TPS dose not
take into account the tissue-air interface, the breast surface would be underdosed during
the treatment.

Table 9.3: Comparison of skin diode, EBT3 film and MOSkinTM detectors doses and THE
percentage difference with the TPS dose.
Detector
Position

TPS
dose
(cGy)

Skin diode
dose(cGy)

%Difference
with TPS

MOSkin
dose(cGy)

%Difference
with TPS

EBT3
dose(cGy)

%Difference
with TPS

1

96.6

85.2

11.7%

91.2

6.4%

75.5

21.7%

2

100.5

98.6

1.8%

80.9

19.5%

76.2

24.1%

3

106.6

103.7

2.6%

117.9

-10.6%

113.2

-6.2%

4

137.9

135.6

1.6%

124.8

9.5%

153.8

-11.5%

5

138.9

137.9

0.7%

120.3

13.4%

133.7

3.7%

6

66.9

61.4

8.1%

70.2

-4.9%

97.5

-45.8%

It is found that the MOSkin doses were also lower than TPS values except at two points.
The lower values are due to the lack of backscatter during BT treatment while the
calculation of the TPS assume a full scatter condition. The measured skin dose was lower
than calculated by the four TPS points (ranging from -6% to -24% under-dosed), with a
standard deviation ranging from 0.5% to 2%, while two points recorded higher doses (5%
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and 9% higher than TPS doses), in locations where any small deviation on the detector
position can lead to a high dose discrepancy. The effective measurement depth of EBT3
film is calculated to be 0.153 mm [190], which is larger than the required depth for skin
dosimetry (0.07 mm). The uncertainty of dose measurement with EBT3 films ranged
between 0.5% to 7%, which is in an agreement with previous studies which claim that the
uncertainty of EBT film dose measurement varies from 3.3% to 7% [197].
9.1.2.4 Discussion
In this study, the use of skin diode detector on the surface of a breast phantom undergoing
HDR brachytherapy treatment has been achieved. The study was carried out to assess the
breast skin dose and to compare the skin dose with expected planning system doses,
MOSkin-measured doses and EBT3 film doses. It was observed that the delivered dose
to the skin during breast HDR brachytherapy is less than the TPS estimated values, which
is primarily due to the lack of backscatter during the treatment while the TPS calculation
is carried out with an assumption of full scattering. In addition, the TPS determins the
dose distribution in a homogenous medium. This could have an impact on therapies where
the target volume is near to the surface.
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9.2 Skin dose measurement with Skin Diode Dosimeter during VMAT
breast treatment
External beam radiotherapy (EBRT) is a high-energy ionising radiation treatment
technique primarily used for the treatment of cancers. In-vivo dosimetry (IVD) is
increasingly gaining importance as radiotherapy becomes more complicated. IVD is used
to detect significant treatment errors, to evaluate clinically important discrepancies
between predicted and delivered dose and to register the total dose received by the
patients. The AAPM Task Group (TG) 40 recommended that clinics must have access to
in-vivo dosimetry devices [198]. The skin is at potential risk of skin toxicity during
radiotherapy, with consequences such as erythema, necrosis and basal cell carcinoma
[199, 200]. It is of high importance to deliver a lethal dose to the target at a certain depth
in the tissue, but this is always achieved at the cost of the danger of increasing skin
reactions.
Volumetric-modulated arc therapy is a treatment technique that involves the rotation of
the linear accelerator gantry around the patient accompanied with the continuous variation
of dose rate, MLC apertures, and gantry rotation speed during the dose delivery [201,
202]. This technique allows the dose to the target area to arrive at the target volume via a
wide area of skin, instead of all arriving through the same area of skin equal to the beam
area. According to Otto [202] this technique leads to a reduction in treatment time of
around 1.5-3 minutes for a 200 cGy fraction, which in turn decreases the intra-fraction
movement and discomfort of the patient.
In breast radiotherapy, the skin dose is an issue. While the skin is considered to be an
organ at risk in most cases. In some cases, it must be irradiated with therapeutic doses.
When a Three-Dimensional Conformal Radiation Therapy (3D-CRT) distribution of dose
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would be not clinically effective, a VMAT delivery technique can be utilised for the
treatments to improve the dose distribution, but this may raise a skin dose problem [203].
The epitaxial skin diode detectors could be a good alternative to traditional in-vivo skin
dosimeters for EBRT. The benefits of using an epitaxial skin diode detector are its small
physical volume and a water-equivalent depth of 70 µm, plus it’s advantage of providing
real-time dosimetry.
9.2.1 Materials and Method
In this study, three skin diode probes were used, which were connected to TERA readout
system which in turn connected to the laptop. To obtain the skin dose, the skin diode
detectors were positioned at five different positions at the surface of the female
anthropomorphic phantom of tissue-equivalent material illustrated in Figure 9.10, with
100 cm SAD and utilising TERA readout system.
A simulated VMAT breast radiotherapy treatment was carried out and in-phantom
measurements were performed utilising the anthropomorphic female phantom. A plan for
VMAT was created using the adaptive convolve algorithm using the Pinnacle computer
package. To create a left breast radiotherapy treatment plan, CT imaging of the
anthropomorphic phantom was performed. The adaptive convolve algorithm is a modified
version of the Collapsed Cone Convolution (CCC) dose calculation algorithm,
implementing a new approach in which the speed of calculation improves with almost the
same calculation accuracy.
Computed Tomography (CT) scans of the phantom were performed in a supine position
with a 2 mm slice thickness as shown in Figures 9.11 and 9.12. CT images were
subsequently moved to the TPS. According to the International Commission on Radiation
Units and Measurements 50 (ICRU 50) recommendations, the goal of the VMAT
optimisation was to obtain a high homogeneity of dose distribution inside the target
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volume, in addition to reduce hot dose spots inside the treated volume [204]. A Varian
Linear Accelerator was used with 6 MV photon beam, and the dose rate was set at 600
MU/min. The prescription was 330 MUs per fraction for 25 fractions. A VMAT plan
similar to a clinical case was created for left breast therapy. It consists of four partial arcs:
the first arc: 30˚-320˚, second arc: 320˚-30˚, third arc: 100˚-150˚, fourth arc: 150˚-100˚,
with different MU at each rotation.
Four positions on the left breast (P1, P2, P3 and P5) were examined and one position on
the right breast (P4) to account for scattered dose was measured by placing the dosimeter
on the anatomical inner side of the contralateral breast. To obtain good reproducibility
and accuracy, the positions of the dosimeters were fixed by placing a marker on the
phantom surface as shown in Figure 9.15. Before the VMAT breast treatment, three skin
diode detectors were calibrated at the reference condition utilizing a Varian linear
accelerator. The skin diode measurements were compared with the Monte Carlo
calculated values, TPS, dose readings with films and optically stimulated luminescence
dosimeter (OSLD).
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Figure 9.10: Anthropomorphic female phantom.

Figure 9.11: Sagittal CT view of the phantom.
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Figure 9.12: Illustration of the beam configuration and dose in the target volume.

Figure 9.13: Positioning of the skin diode detectors on the anthropomorphic female phantom.
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9.2.2 Results
The average calibration factor for the skin diode dosimeters utilised in this study was
1287 ± 30 pC/cGy. This study evaluated the performance of skin diode dosimeter and it
was found to be clinically acceptable. At ICCC, Monte Carlo simulation using GEANT4
is used as a reliable simulation tool for verification of all treatment plans. Table 9.4
presents the skin dose measured at the five allocated positions on the anthropomorphic
female phantom. In comparison to Monte Carlo estimated dose, both Skin diode and
EBT3 films generally gave good agreement. As shown in Figure 9.16, the percentage
difference between MC simulation and skin diode for P2, P4 and P5 were 1.5%, 2.3%
and 1.2% respectively. While, the percentage difference between MC simulation and
EBT3 films were 0.69%, 0.63% and 5.5% respectively. The results for the OSLD deviated
from the MC simulation by 42% for P2, 5% for P4 and 39% for P5. Whereas, this
difference increased for TPS predicted dose and reached 62%, and 45% for position 2 and
position 5 respectively. However, the TPS underestimated the dose at position 4
(contralateral breast) with a difference of 87%.
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Table 9.4: Skin dose measurements at five positions on the surface of the phantom.

Detector

Skin

OSLD

EBT3

TPS

Monte

Position

diode

(cGy)

Film

(cGy)

Carlo

(cGy)

(cGy)

104.2

154.1

106.1

P2

99.9

143.7

102.1

P3

118.7

161.4

120.1

P4

46.8

50.3

P5

103.9

146

% Dose Difference (%)

P1

90
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50

(cGy)

37.6

101.4

48.2

6.24

47.9

111

57.4

105.2

Skin diode
OSLD
EBT3 film
TPS

Position 2

Position 4

Position 5

Figure 9.14: Percentage dose difference between MC dose and the measured dose for: skin
diode, OSLD, EBT3 film and TPS, at points 2, 4 and 5 in the anthropomorphic phantom during
VMAT.
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9.2.3 Discussion
Skin reactions from skin dose during radiotherapy are a serious clinical problem during
various cancer treatments. Therefore, precise prediction of the skin dose becomes
clinically significant during treatment planning.
The forgoing experiment was done to identify the suitability of the skin diode detectors
for skin dose measurement during breast radiotherapy using VMAT plans. In the female
anthropomorphic phantom, using the treatment plan carried out by the VMAT TPS, there
was a large discrepancy between the measured and the calculated doses by the TPS in the
first few millimetres. The TPS underestimated skin doses for the measured positions. The
Pinnacle is known to be inaccurate at calculating dose at the surface of the phantom. This
can be explained by the complexity of measuring and estimating the accurate dose at the
air-tissue interface and the limitation of the TPS for skin dose measurements up to 3 mm
depth. A study conducted by Shiau et al., assessed the accuracy of the TPS predicted
doses [205]. In addition, the accuracy of the dose calculation for the TPS in the shallow
region was found to depend on the dose calculation algorithm. At depths of less than 3
mm, variations larger than 10% between calculations and measurements can be detected;
at a deeper depth, the efficiency of the dose calculation is more reliable. Shiau et al.
indicated that if electron contamination is taken into account, the accuracy of the TPS
calculation can be enhanced due to the fact that the contamination radiation from the head
of the machine, air and backscattered radiation from the patient are the key sources of
skin doses [205]. Several studies have stated that the physical characteristics of OSLD for
dosimetry are good, including linearity, good reproducibility and low dose rate and
energy dependence [206-210]. Compared to films and TLDs, the OSLD, which achieves
stability at about 16 minutes after irradiation, has a simpler and less-time consuming
reading process [206] [211]. The results showed that OSLD dosimeter recorded higher
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skin doses as compared to films, skin diodes and Monte Carlo calculated doses for all five
positions. This over response is due to the large water- equivalent depth of the OSLD
dosimeter in comparison to the small water equivalent depth of skin diodes and EBT3
films and due to the inherent packaging and build-up of the OSLD themselves. The
effective measuring point of the dosimeter can have a major impact on the measured skin
dose. EBT3 films and skin diode dosimeters are in good agreement with the MC
calculated doses.
In-vivo dosimetry is crucial for the accurate estimation of skin dose during EBRT.
Finally, the outcome of this experiment suggests that skin diode dosimeters are a
promising quality assurance tool for skin dose measurement during VMAT plans,
provided allowance are made for known sensitivities and influencing factors.

9.3 Conclusion
Actually, there is no routine in-vivo system of high dose rate brachytherapy, which may
lead to unknown errors and complications throughout therapy session due to the high
radiation doses that are encountered in a very small area. Skin diode dosimeters display a
number of characteristics indicating suitability for skin dose measurements during HDR
brachytherapy treatment. They have a small water-equivalent depth of 0.07 mm, in
addition, they have a thin dosimetric volume able to measure dose in a steep dose gradient
region. This chapter introduces a method for in-vivo anterior rectal wall dosimetry during
TRUS high dose rate prostate brachytherapy utilising three skin diode dosimeters attached
to a TRUS probe working as a Dual-Purpose Probe. Skin diode detectors demonstrated
potential in-vivo dosimetry abilities compared to the existing clinical dosimeters, with an
acceptable agreement with the doses of the treatment plan and low DTA values.
179

In this chapter, the use of skin diode detectors on the surface of the breast phantom
undergoing HDR brachytherapy treatment has been achieved. The experiment was carried
out to assess the breast skin dose during breast HDR-BT and to compare the skin diode
doses with the expected planning system doses, EBT3 film and MOSkin dosimeters. The
findings show that the delivered doses to the skin during breast HDR brachytherapy is
less than the TPS estimated values, since TPS accounts for dose distribution in a
homogenous medium. This could have impacts for therapies where the treated volume is
near the surface. A further investigation which includes real-time in- vivo measurements
for real patients should be performed.
A study evaluating the performance of skin diode dosimeters in simulated breast
treatment during VMAT was also performed. In this study, a good agreement was found
between the skin diode doses, EBT3 films and Monte Carlo calculated doses. It is found
that skin diode detectors are a clinically promising dosimeter for skin dose measurements
during VMAT plans.
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CHAPTER 10: Conclusion and Suggestions for Future Work
Over the past few decades, radiotherapy has been one of the primary cancer treatment
options, with more than 50% of patients receiving some form of radiotherapy as part of
their cancer treatment strategy.
Owing to the growing complexity of treatment modalities in radiotherapy, detectors have
been increasingly needed to perform quality assurance to ensure that patients are treated
accurately and safely. Current techniques in radiotherapy include; small field sizes, high
dose gradients and varying energy intensities and rates of dose delivery. For this purpose,
the ideal dosimeter should show high spatial resolution, high linearity, reliability, and
radiation hardness. Silicon detectors have been commonly utilised for radiotherapy
dosimetry and have several positive traits as a dosimeter; however, a limitation of silicon
detectors is that they (slowly) reduce in sensitivity with accumulated dose.
During treatment delivery, online verification is required. Any errors can be identified in
real-time using a verification system, and the treatment can be stopped immediately and
re-planned to address the error. In the light of the importance of in-vivo dosimetry for
precise delivery of the radiation dose and reduction of patient' over-dosing during
radiotherapy, small-volume and high- resolution in-vivo detectors are of great interest.
The initial objective of this study was to characterise the new n-type skin diode detector
under various clinical radiation beams, including high-energy photon beams from a
Linear Accelerator, orthovoltage (kV) x-ray beams from a Gulmay DX3300 x-ray
machine and gamma rays from a flexitron Ir-192 brachytherapy source. The single skin
diode detectors were manufactured using n-type silicon substrates of 0.38 mm thickness
with sensitive 1 x 1 mm2 areas and an epitaxial layer of 0.0065 mm thickness. Skin diode
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detectors were packaged by using an innovative “drop-in” technology developed at
CMRP.
This thesis has provided an overview of prostate cancer and treatment options used for its
treatment, and a review of brachytherapy sources, treatment planning systems and the
TG43 dose calculation formula. Following that, an overview of breast cancer and the
treatment options used for its treatment has been provided, followed by some details about
skin dosimetry, in-vivo dosimetry and the physics of silicon diode detectors and the
available CMRP silicon detectors. Finally, introduction and analysis have been provided
about the Monte Carlo simulation and GEANT4 code used in this thesis.

A description

of the instruments used in this thesis was covered in Chapter 3. The new n-type skin diode
detector, MOSkin detectors and patient phantoms used have all been introduced and
described in chapter 3. The readout systems used (AFE DAQ, OneTouch, and TERA)
and details about the experimental field arrangements have also been presented.
In Chapter 4 The new n-type skin diodes were characterised by assessing their electrical
properties by performing current-voltage (I-V), and capacitance-voltage (C-V)
measurements. An analysis of the I-V and C-V characteristics of the skin diode detector
was carried out. It is found that the detector current showed a breakdown at -20 V, so care
is taken in experimental set-ups to avoid use of the detectors at such an extreme negative
bias. The skin diode detector exhibited the ideal p-n junction trend, with current
increasing as a function of increasing applied voltage.
In Chapter 5, the depth dose response and angular response for two detector models, the
liquid water model and the silicon detector model, were studied to test the validity of
Monte Carlo simulation. The angular response of the two models in 30˚ increments was
studied at angles ranging from 30˚ to 330˚. For the liquid water model, an isotropic
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response was seen in the results. By comparison, the angular response for the silicon
model was within 4% of the average response
In Chapter 6, An investigation into characteristics of a new n-type skin diode dosimeter
was described, aimed at clinical application in EBRT. These characteristics include
detector calibration, linearity, PDD and OF. The experiments were performed with a
Varian Truebeam LINAC operating at 6 MV in FF and FFF modes. The skin diode
showed a good (i.e.linear) dose response with a deviation from straight-line behaviour of
less than 1% over a dynamic range between 5 cGy and 500 cGy for 6 MV FF and FFF
photon beams. The skin diode uncertainty for measuring the PDD was less than 1.7%
when measuring beyond the build-up region, compared to CC13 ion chamber readings.
For the 6 MV and 6 MV FFF photon beams, the observed correlation coefficients R2 of
charge vs. dose for the skin diodes were 0.9994 and 0.9999 respectively. It is noticeable
that the skin diode out-put factor produced a good agreement (within 5% of the ion
chamber measurements) for all field sizes larger than 3 x 3 cm2 for 6 MV FF and FFF
photon beams.
Chapter 7 continued the investigation of the characteristics of the new skin diodes in
EBRT. The characteristics studied in this chapter were energy dependence, dose per
pulse, and angular dependence. For 6 MV and 6 MV FFF modes respectively, the
sensitivity of skin diode varied by 5.5% and 11% over the studied range of dose per pulse.
The calculated angular dependence showed that the sensitivity difference between the
front and back face of the skin diode detector was 20%, with a variation of 10 % for ± 60˚
orientation angles of the detector. The kilovoltage beam for the energy-dependence study
was produced by a Gulmay DX3300 orthovoltage x-ray therapy system at ICCC. A
radiation dosimeter’s energy dependence is significant if the device is utilised for
radiotherapy or diagnostic x-rays of low photon energy. Ideally, for a range of energies,
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it is desirable to have energy independence, but in reality, most dosimeters have a slightly
higher dose-response at low energy due to the increase of photoelectric capture crosssection at low photon energies. The skin diode has demonstrated similar energy
dependency in the literature to MOSkin dosimeters. The skin diode's response for 50 kV
photons was 1.34 times higher than the response to 6 MV photon energy.
In Chapter 8, the dosimetric characteristics of the new skin diode dosimeters were
investigated under an Ir-192 HDR brachytherapy source. The skin diode dosimeter was
capable of measuring the dose-response at different depths with reasonable accuracy. In
both polar and azimuthal directions, the angular dependence of the skin diode dosimeter
was investigated, and it was noticed that the responses of the skin diode are within 5%
and 4% for polar and azimuthal directions respectively. Our studies demonstrate that skin
diode dosimeters work well in an HDR brachytherapy setting, indicating that they are
acceptable as a clinical dosimetry system for in-vivo dosimetry.
In Chapter 9, a comparison was made of TPS calculated dose with skin diode detectors
placed on a TRUS probe to form a Dual-Purpose Probe in an HDR Prostate BT treatment
setting. Furthermore, the dosimetric accuracy of the new skin diode dosimeters to
measure skin dose during high dose-rate breast brachytherapy was also assessed. Finally,
in breast radiotherapy, the use of advanced treatment techniques such as VMAT has
become more widespread, but this has increased requirements for accurate dose
measurement estimation.
VMAT has a more complex dose distribution and existing TPSs are poor in predicting
the skin doses in such a situation. Real-time in-vivo skin dosimetry has been shown to
have a major benefit and is suggested for checking the correctness of treatment delivery
in real-time by observing skin doses during each treatment fraction delivery.

184

On the whole, because of the small size and good spatial resolution of the skin diodes, it
was noticed that they can be utilised in steep dose gradient areas. The new n-type epitaxial
skin diode dosimeter proves to be a good and effective in-vivo real-time skin dosimetry
tool to prevent certain systematic set-up errors during the treatment of breast and prostate
cancer with EBRT and HDR BT.
In future, different epitaxial layers and areas can be designed to increase the sensitivity
of the detector. In addition, further characterisation of skin diodes’ performance should
be undertaken to allow a complete characterisation for different clinical treatment
scenarios.
Since this work has been done, a new model-based calculation algorithm TG186 TPS for
brachytherapy dose calculation in addition to the existing TG43 dose calculation formula
at the St. George Hospital was used. So, a study including a comparison of measurements
vs TG43/TG186 is of great interest to check details of the extent of agreement.
Implementation of this system during clinical patient treatment and gathering real patient
data for evaluation is an obvious next step for skin diodes. This can be done by comparing
in-vivo patient skin dose measurements with skin diode detectors, EBT films and
MOSkins for HDR breast brachytherapy, in order to track agreement between TPS
predicted doses and the measured dose throughout the course of the patient’s treatment
(7-days). Important changes in patient anatomy occur due to swelling over the 7-day
treatment interval and this can change extent of absorption, backscattering, dose build-up
etc. These effects need to be carefully measured and analysed by suitable detectors. Based
on the results we have seen in the work summarised in the preceding chapters using the
new n-type epitaxial skin diode, the use of skin diode is likely to be extremely valuable
in studies that include previous effects.
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